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(iii) Abstract
Background: Heme oxygenase (HO) functions in the rate-limiting step in the
2+metabolism of heme to form biliverdin, carbon monoxide and free iron (Fe ). 
HO has an inducible form HO-1 and constitutive forms HO-2 and HO-3. HO-1 is 
highly conserved and essential for life. It has been suggested that in addition to 
the metabolism of heme, HO-1 may have anti-oxidant and anti-inflammatory 
roles. Induction o f HO-1 in pulmonary, hepatic and brain tissues has been shown 
to reduce damage under ischaemic and inflammatory conditions.
Hypothesis: Loss o f appropriate regulation of HO-1 may cause a reduction in HO- 
1 levels resulting in an increase in reactive oxygen species in the gastrointestinal 
tract leading to the development of uncontrolled inflammation. This reduction in 
HO-1 may play a role in the development of inflammatory bowel disease, 
colorectal cancer and Barrett’s oesophagus.
Aims and Methods: Immuno-staining was used to compare the expression of 
HO-1 and HO-2 in normal colon, inflammatory bowel disease (IBD) and 
colorectal cancer. A similar comparison was made between biopsies from normal 
oesophagus and Barrett’s oesophagus. In all cases the intensity of staining was 
scored in both the lamina propria and the epithelial cell layer. Western blotting 
was used to assess HO-1 protein production in the colon cell line HT29.
Results: HO-1 was expressed in normal colon and oesophageal tissue in the 
epithelial cell layer and in some of the inflammatory cells o f the lamina propria. 
HO-1 was also expressed in the blood vessel walls and the parasympathetic 
ganglia in the submucosa in healthy colon. There was a significantly increased 
expression in the lamina propria in IBD, the epithelial layer in colorectal cancer 
and in both the lamina propria and epithelial cells o f Barrett’s oesophagus. The 
colonic cell line HT-29 expressed HO-1 and the expression was further increased 
by exposure to ultra-violet light.
Conclusions: HO-1 is increased in conditions o f inflammation or cancer, 
suggesting an appropriate physiological response to reactive oxygen species rather 
than a deficiency state in HO-1.
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Introduction
1 INTRODUCTION
1.1 Normal structure of the gastro-intestinal tract
The gastrointestinal tract (GI tract) is a muscular tube that stretches from the 
mouth to the anus. There is a common pattern to the structure along its length, 
which consists of 4 layers. The layers from the luminal surface inwards are: the 
mucosa, the submucosa, the muscularis and the adventitia or serosa. (Figure 1, 
Wheater et al 1979). The muscular parts of the tract are relatively similar 
throughout the gut; however the character and function of the mucosa vary along 
its length. There are several points at which there is an abrupt change in the type 
of mucosa: at the gastro-oesophageal junction, the gastro-duodenal junction, ileo- 
caecal junction and the recto-anal junction. In other parts of the GI tract such as 
the small bowel there are gradual changes in the character of the mucosa.
The mucosa consists of 3 layers: (1) the epithelium lines the lumen, (2) the lamina 
propria which is made up of supportive connective tissue and is the site of many 
inflammatory cells and (3) the muscularis mucosae which is a very thin layer of 
smooth muscle capable of causing small scale movements of the mucosa and 
offering some resting tone which holds the mucosal folds in place (see Figures 2 
and 3).
The submucosa is a layer of connective tissue that supports the structure of the 
mucosa and contains the blood vessels, nerves and lymphatics. The muscularis is 
made up of two smooth muscle layers, the inner being circular and the outer
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longitudinal. The co-ordinated contraction of these smooth muscle layers gives 
rise to the peristaltic waves that lead to the progression of the luminal contents 
along the GI tract. The adventitia is the outer layer of the GI tract and is made up 
of connective tissue: within this layer are the larger blood vessels and nerves. 
Post-ganglionic parasympathetic nerves supply the mucus glands and the smooth 
muscle of the muscularis mucosae and arise from the parasympathetic plexus 
within the submucosa (Meissner’s plexus). The parasympathetic nerves supplying 
the larger circular and longitudinal muscle layers o f the muscularis arise from the 
myenteric plexus which is usually found between the circular and surrounding 
longitudinal layers.
Figure 2 and 3 show haematoxylin and eosin staining of normal terminal ileum 
and colon. This is the standard staining technique used for histological analysis of 
tissue. The essential structural elements of the mucosa are labelled within figure; 
there is a large lymphoid aggregate and many villi cut in cross-section (Figure 2). 
Epithelial cells line the luminal surface and just below this is the lamina propria 
containing inflammatory cells and stromal components. Figure 3 shows the 
structure of the normal colonic mucosa. There are no villi in the colon; the crypts 
lined with epithelial cells are clearly seen, cut both in cross-section and 
longitudinal section. Beneath the lamina propria the muscularis mucosae is 
marked. Deep to the muscularis mucosae is the submucosa and blood vessels are 
marked in this region.
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Figure 1 The general structure of the gastrointestinal tract in cross section.





Figure 2 Normal terminal ileum stained with Haematoxylin and Eosin
(A) Villus in cross-section, (B) Villus in longitudinal section.
(original magnification of 128 x)
Gland
Figure 3 H + E slide to identify structures within the normal colonic 
mucosa: EP epithelial cell, MM the muscularis mucosae, BV blood vessel in 
the the submucosa, LP the lamina propria (original magnification o f 128 x)
18
Introduction
1.2 Inflammatory Bowel Disease
Crohn’s disease and ulcerative colitis are diseases of chronic inflammation of the 
gut, together they make up inflammatory bowel disease. Their aetiology remains 
unclear but is influenced by both genetic and environmental factors. Combined 
incidence rates in the Western world are in the order o f 4 -10  new cases per
100.000 per year and prevalence is between 40 and 100 per 100,000 of 
population. These conditions are more common in the developed world, some of 
the highest rates being found in Scandinavia. The major defining feature of UC is 
that inflammation is confined to the colon, whereas CD inflammation can occur in 
any part of the gut from the mouth to the anus.
1.2.1 Characteristic histological features o f IBD
In UC acute and chronic inflammation are confined to the mucosa involving 
polymorphonuclear leukocytes and mononuclear cells. Other classical histological 
features include crypt abscesses; mucosal gland distortion and goblet cell 
depletion (see Figure 4). The inflammatory change almost always involves the 
rectum and variable amounts of the more proximal colon. In CD the inflammatory 
change can involve the full thickness of the bowel wall in any part of the gut. 
Classical CD defining lesions include granuloma formation and aphthous 
ulceration. Diseased areas of gut may be surrounded by normal tissue.
1.2.2 Clinical presentation and diagnosis
Both UC and CD are characterised by episodes of uncontrolled inflammation 
affecting the gut wall. UC tends to present with a change in bowel habit,
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Crypt Abscess
Glandular Distortion
Figure 4 H+E stained colonic biopsy from a patient with UC.
This slide shows a crypt abscess, glandular distortion, there is also marked 
inflammatory cell infiltrate throughout the lamina propria 
Original magnification 128x.
Figure 5




producing a watery, bloodstained stool, of increased frequency. This may be 
accompanied by lower abdominal pain. CD most commonly affects the ileo- 
caecal region i.e. the end of the small bowel as it joins the colon, this may result in 
abdominal pain, weight loss and possibly a change in bowel habit. If CD affects 
the colon then it may present in a similar fashion to UC and the diagnosis will 
then depend on the distribution of the inflammatory changes and on histology of 
colonic biopsy specimens. When CD affects other parts o f the gastro-intestinal 
tract it may present in a less obvious way. Inflammation caused by CD may lead 
to some regions o f the bowel becoming narrowed to form a stricture. Strictures 
can give rise to postprandial pain. CD of the upper gut can also give rise to 
nausea, weight loss and epigastric pain.
Diagnosis of IBD depends on histological features o f biopsy material and the 
distribution of the inflammation. Endoscopic examination o f the colon 
(colonoscopy) is the primary diagnostic tool in colonic IBD. Using the video 
endoscope it is possible to view the mucosal lining in real time and take tissue 
specimens (biopsies). The small bowel is relatively inaccessible to conventional 
endoscopic techniques and diagnosis often depends on radiological tests, which 
can indirectly demonstrate which parts o f the gut are affected by inflammation.
1.2.3 Medical therapy and IBD
Although UC and CD were first clearly defined in the 1930s, it was not until the 
1940s that effective medical therapy became available. Surgery for severe 
inflammation was not always successful and IBD had a significant mortality. In 
the 1940s it was discovered that sulfasalazine, a drug used to treat arthritis, also
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reduced bowel inflammation (Svartz, 1954 ). This fortuitous observation led to the 
development o f a family of agents designed around the 5-aminosalicylate 
structure. In the 1950s, following the work o f Truelove and colleagues in Oxford 
it was shown that severe inflammation in IBD could be effectively treated with 
systemic steroids, usually prednisolone (Truelove, 1960). 5-aminosalicylic 
acid agents and steroids formed the mainstay of medical therapy for IBD over the 
next 40 years.
Recurrent bouts of inflammation necessitating repeated steroid treatments can 
lead to long-term steroid side effects such as osteoporosis, muscle wasting, 
adrenal suppression, diabetes mellitus, hypertension and skin fragility. In the last 
decade there has been renewed interest in other forms o f immuno-suppression, 
most notably the use o f azathioprine. Used as maintenance therapy, once 
remission has been achieved, it reduces the likelihood o f further flares of 
inflammation and avoids the problems associated with steroid therapy. There is 
still an essential role for the use of short courses o f steroids to induce remission in 
IBD. Maintenance of remission can then usually be achieved by continuing 
azathioprine or high dose 5 aminosalicylate agents. Other immunosuppressant 
agents have been tested: in acute UC intravenous cyclosporin can delay the need 
for surgery but is not thought to greatly change the overall outcome. Tacrolimus 
has proved to be disappointing. Some therapies have been shown to be 
particularly useful in CD. Antibiotics such as metronidazole and ciprofloxacin 
have been shown to improve CD especially peri-anal disease. This observation 
supports the role o f bacteria in the aetiology of CD, which will be further
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discussed below. Methotrexate and thalidomide have also proved to be useful 
second-line therapies in CD.
1.2.4 Advent of biological therapies
In the last 10 years there have been great advances in the understanding of the 
control of inflammation. This has led to the design of drugs targeted at individual 
cytokines. The best example is the action of a chimeric antibody specific to 
Tumour Necrosis Factor alpha (TNFa), a therapy originally developed to treat 
rheumatoid arthritis. When given as an intravenous infusion over 3 occasions, it 
achieved a clinical response in 81% of cases and remission in 48% (Targan, 
Hanauer et al. 1997). It has been found to be particularly successful when treating 
fistulating CD.
1.2.5 Natural history o f IBD
Patients with severe UC have a 25- 40% lifetime rate of colectomy. Surgery is 
reserved for 4 types o f patients with IBD. Firstly, for patients who fail to achieve 
remission with medical treatment. Secondly, those who present with the toxic 
megacolon, a complication of severe colonic inflammation in which a sudden 
dilatation of the colon occurs risking perforation and death. Thirdly, fibrotic 
strictures can develop after years of grumbling inflammation; these do not 
respond to anti-inflammatory medication and if they are causing symptoms of 
bowel obstruction will require surgery to restore a functioning lumen. Finally, 
surgery may be required for those patients who develop colorectal carcinoma as a 
complication of a long duration o f colitis. Most patients who require surgery for 
CD will need a second operation within 20 years. The risk o f further surgery in
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CD can be reduced by maintenance azathioprine (Travis 2001) and the cessation 
o f smoking (Cosnes, Beaugerie et al. 2001). Unlike for UC, surgery in CD can 
never be considered curative; the disease is not confined to the colon and 
therefore can recur elsewhere.
1.2.6 Pathogenesis of IBP
1.2.6.1 Genetics and IBP
Twin studies show that there is a major genetic influence in IBD. The chance of 
both twins having CD is much higher for monozygotic compared to dizygotic 
twins. Family studies show that first-degree relatives of a patient with IBD are 
tenfold more likely to develop IBD than normal subjects. Within the last couple of 
years exciting discoveries linking CD to a particular gene defect have been made. 
Mutations of the NoD2 (nucleotide oligomerisation domain) gene on chromosome 
16 have been linked to an increased risk of CD (Hugot, Chamaillard et al. 2001; 
Ogura, Bonen et al. 2001). Mutations in this region occur in 23 % of patients with 
CD compared to only 7% of normal subjects. The NoD2 gene codes for a receptor 
specific to the lipopolysaccharide of bacterial cell walls, and may have a role 
preventing bacterial invasion of the gut wall. Activation of this receptor is thought 
to result in the up-regulation of NFkB. The most common mutation is a frame 
shift change, which results in truncation of the last 3% of the protein and a 
decrease in the LPS-induced activation of NFk B. This is somewhat surprising, 
as this would appear to reduce any inflammatory response to bacteria. Although 
this defect remains incompletely explained, it does represent the first genetic 
abnormality identified which has a functional significance related to IBD. More 
recently the phenotype of CD associated with the mutations on the NoD2 gene
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associated with ileal disease has been characterised by two groups (Ahmad, 
Armuzzi et al. 2002; Cuthbert, Fisher et al. 2002). It may be that future genetic 
analysis will be able to identify specific subgroups within IBD, giving prognostic 
information to guide the selective use of medical or surgical therapy.
1.2.6. 2______ Auto-immune mechanisms and IBD
It has been suggested that several of the features of UC could be accounted for by 
an auto-immune process directed against a self antigen such as mucin, goblet cells 
or colonocytes (MacDonald, Monteleone et al. 2000). It has long been recognised 
that the anti-neutrophillic cytoplasmic antibody is associated with UC, although 
its levels do not correlate with disease activity (Roozendaal, Pogany et al. 1999). 
Other significant antigens have proved to be difficult to identify. It is now thought 
that the most significant drive to inflammation in Crohn’s disease is the presence 
of foreign antigens rather than an auto-immune process.
1.2.6. 3______ Role o f intestinal epithelial cells
A single layer o f colonic epithelial cells is the only barrier between the gut lumen 
and the underlying mucosal immune system. The colonic epithelial cells are 
exposed to the luminal contents o f the gut (for example, bacteria) and are capable 
of producing cytokines (such as MCP-1), which then can influence the behaviour 
of sub-epithelial lymphoid tissue. In this way they may act as early warning 
sentinels for the immune system. Interesting data produced by Ward’s group at 
Bath have shown that the production of COX-2 by the intestinal epithelial cells 
can be inhibited/down-regulated by the Th2 cytokines IL-4, IL-10 and IL-13 via a 
PI3K dependent mechanism (Weaver, Russo et al. 2001).
Expression of HO-1 in the GI tract 25
Introduction
1.2.6.4 Environmental factors and IBD
Sheltered Child Hypothesis
Environmental conditions particularly in the early years o f life appear to influence 
the risk of developing IBD. A study of the availability of a hot water tap in the 
childhood home showed that individuals who had access to hot water had a 
fivefold increased odds ratio of developing CD compared to those without (Gent, 
Hellier et al. 1994). The study population had been bom in the 1950s and 1960s 
and so not all had access to such amenities. Other studies have shown a reduced 
rate of Helicobacter pylori seropositivity in CD patients compared to UC and to 
individuals without IBD. Helicobacter pylori is transmitted by the faeco-oral 
route and so can be used as a surrogate marker of poor hygiene. Again, it can be 
argued that the low seropositivity o f H.pylori associated with CD shows a link 
between good childhood hygiene and CD (Feeney, Murphy et al. 2002, Table 1). 
It has been suggested that such conditions may delay the exposure to previously 
prevalent childhood infections. It is possible that when encountered later in life 
such infections could trigger inappropriate inflammation. This could occur 
directly by affecting the GI tract or as a result of the development o f an antibody 
raised against an infective organism that inappropriately cross-reacts with a host 
protein. This theory could account for the rising prevalence of CD in the Western 
world over the last 50 years. Interestingly over this period the prevalence of UC 
has remained relatively unchanged (Logan, 1998).
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A case-control study of childhood environmental risk factors for the development 
o f inflammatory bowel disease.
Feeney MA, Murphy F, Clegg,AJ, Trebble TM, Sharer NM and Snook JA 
European Journal o f Gastroenterology and Hepatology 2002.
Table 1
Odds ratios (with 95% confidence intervals)
Crohn’s Disease UC
Helicobacter Pylori 0.18 (0.06-0.52)* 0.91 (0 .38-2.16)
Appendectomy 0.53 (0.16-1.73) 0.05 (0.01-0.51)#
Childhood eczema 2.81 (1.23- 6.42)+ 1.83 (0.73- 4.59)
(*P  =0.002, #p=0.011, + p=0.014)
Smoking and IBD
Smoking seems to alter the risk o f IBD and to affect which type o f disease an 
individual develops. In many studies an excess risk o f CD has been demonstrated 
in smokers and o f UC in ex-smokers (Fiocchi 1998; Bridger, Lee et al. 2002). 
Smoking cessation can reduce the risk of further surgery in CD (Cosnes, 
Beaugerie et al. 2001). Paired siblings both suffering from IBD but with a 
different smoking history demonstrate that smoking may determine which 
phenotype of disease develops in a genetically susceptible individual. O f sibling 
pairs discordant for both type o f IBD and smoking history those who smoked 
were far more likely to have CD than UC (this pattern was seen in 21 out of 23 
such sibling pairs) (Bridger, Lee et al. 2002).
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Infective organisms
Persistence of infective organism has been suggested to play a major role in the 
pathogenesis o f CD. The IBD research group from the Royal Free Hospital have 
suggested that CD is a granulomatous vasculitis caused by the persistent presence 
o f the measles virus, either from wild type infection or from a live-attenuated 
vaccine such as the Measles Mumps Rubella vaccine (MMR)(Wakefield and 
Montgomery 2000). Other research groups have challenged this theory. Even 
using sensitive PCR (polymerase chain reaction) detection techniques no 
independent group has been able to identify the measles virus in CD tissue. 
Epidemiological evidence has also failed to find a link with the vaccine (Feeney, 
Clegg et al. 1997, Table 2). In this study we compared the vaccination histories of 
140 patients with IBD (83 with CD, 57 with UC) with those o f 280 age and sex 
matched controls selected from the same GP lists. In this well-powered case- 
control study the rates o f measles vaccination were very similar in those with CD, 
UC and subjects without IBD implying that vaccination was very unlikely to have 
been a major risk factor for the development of CD. The odds ratios for measles 
vaccination in CD in UC and in all IBD were all around unity suggesting no 
association between the vaccine and either type o f IBD (table 2).
The other organism which has suggested as a possible cause of CD is the 
Mycobacterium paratuberculosis. This organism is capable o f exciting a 
granulomatous reaction in cattle tissue, in the form o f Johne’s disease. In some 
cases M. paratuberculosis has been isolated from patients with CD (Engstrand
1995), however PCR studies suggest that the presence o f this bacterium is not 
specific to CD (Hubbard and Surawicz 1999).
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A case-control study of measles vaccination and inflammatory bowel disease. 
Feeney M A, Clegg A, Winwood P, Snook J (1997).
Lancet 350(9080): 764-6.
Table 2 (a) Summary of patient details and
Odds ratios ( 95% confidence intervals) for IBD in vaccine recipients
CD UC All IBD
Number of subjects 83 57 140
Median age at diagnosis 19(15-22)* 20 (16-24) 19(15-24)
Measles vaccine 1.08 (0.62-1.88) 0.84 (0.44-1.58) 0.97 (0.64- 1.47)
Table 2(b) Crude vaccination rates and age at first vaccination
IBD group Control group
Rate % Age (months) Rate % Age ( months)
Measles 56.4% 16 57.1% 17
Pertussis 70.7% 5 70.7% 6
Diph/Tetanus 92.9% 6 93.2% 6
This study had a 99% power to detect a 3-fold risk in CD in measles vaccine 
recipients (with a p< 0.05).
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Dysregulated immune response to gut flora
Several forms of evidence suggest the role of gut bacteria in the pathogenesis of 
IBD. (a) The diversion o f the faecal stream via a stoma can allow more distal 
inflammation to settle, especially in Crohn’s disease (Winslet 1994). (b) IL-10 
knockout mice only develop colitis when reared in non-sterile conditions (Kuhn, 
Lohler et al. 1993). (c) Titres o f antibodies to E.coli are raised in patients with 
IBD (Tabaqchali, O'Donoghue et al. 1978). (d) Some strains of bacteria can alter 
the permeability of the gastrointestinal epithelium (Rocha, Laughlin et al. 2001). 
LPS (lipopolysaccharide), which forms bacterial cell walls is a potent stimulus to 
inflammatory cytokine production (Sartor 1995). The NoD2 gene variation which 
codes for a defective LPS receptor may prove to be a link between genetic and 
environmental factors in the causation of IBD (Hugot, Chamaillard et al. 2001; 
Ogura, Bonen et al. 2001).
1.3 Colorectal Carcinoma fCRC)
This is the second most common cause of death from cancer in the UK (after lung 
cancer). Incidence rises with age and the average age at diagnosis is between 60 
and 65 years. There is no great difference in the rates of CRC between the sexes. 
Both genetic and environmental factors influence the risk o f CRC. In figure 5 
(p20) a section form a mucinous colorectal cancer is illustrated. This section has 
been prepared with the standard haemotoxylin and eosin stain. The cells within 
the cancer show a variability o f size and shape and are less organised than the 
cells in normal colonic epithelium.
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1.3.1 Environmental factors and CRC
Immigrants from Japan which has a relatively low rate o f CRC adopt an increased 
risk of CRC when they change to a Westernised lifestyle (Parkin, 1997). It has 
been suggested that diets high in fat and low in fibre may account for the increase 
in CRC in the Western world (Howe, 1992). Fat metabolism may promote the 
formation of carcinogens, which may have a longer time in contact with the 
mucosal surface due to slow transit times associated with low fibre high fat diets 
(Babbs 1990).
1.3.2 IBD and CRC risk
Longstanding colitis is a risk factor for CRC. The risk has been shown to be 
proportional to the duration of the colitis and is greater in those in whom the 
entire colon is affected (Eaden 2001). Other environmental risk factors include 
smoking and excess alcohol intake. Smoking generates oxidant stress and alcohol 
inhibits DNA repair.
1.3.3 Genetic factors and CRC
A family history o f CRC at least doubles the risk o f CRC. Certain families have 
larger numbers o f individuals affected by CRC: and overall 15 % of siblings and 
10% of offspring succumb to CRC. The risk of CRC in the general population is 
just under 6%. A variety of genetic defects have now been identified. However it 
is only a minority o f all colorectal cancers that are associated with inherited 
defects, about 15 %. The other 85% are sporadic in individuals with no family 
history. The two most commonly recognised heritable cancer syndromes are 
familial adenomatous polyposis (FAP) and Hereditary Non Polyposis Colorectal 
Cancer (HNPCC). The APC  gene functions as a gatekeeper and is mutated in >
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85% of all CRCs (Powell SM 1992). In 10 -15% of cases mismatch repair genes 
are mutated. The K -ras gene is defective in 50 % of large adenomas and CRCs. 
Late in the process of carcinogeneis the p53 gene is often mutated, this being 
more often seen in malignant lesions (Grady 2000).
FAP
FAP results from a germline defect in the APC  gene, which is inherited in an 
autosomal dominant fashion. This causes the development of diffuse colorectal 
polyps, usually visible by the second decade. Prophylactic colectomy is 
recommended as without it CRC is almost inevitable, usually before the age of 45 
years (Jang 1997).
HNPCC(Hered\tary Non Polyposis Colorectal Cancer)
This syndrome is also autosomal dominant in inheritance. It is diagnosed by 
clinical criteria (Amsterdam Criteria) (Lynch 1993): 3 successive generations 
affected, at least one first degree relative and one of these being less than 50 at the 
age of diagnosis. It is associated with cancers elsewhere: ovary, uterus, stomach, 
urinary tract and bile duct. Although recognised and diagnosed by clinical criteria 
recently mutations in 5 mismatch repair genes have been identified (Chung 1995).
1.3.4 Natural history and presentation o f CRC
Most CRC are thought to develop through a sequence of changes in normal 
mucosa. First to form an adenoma this then develops into a CRC (Volgelstein 
1988). This sequence of events is supported by the following observations: the 
location of polyps is very similar to that of CRC (two thirds in the left side of the
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colon), resection o f polyps reduces CRC risk, and benign adenomatous tissue is 
sometimes found very close to early CRC. In normal individuals the progression 
from normal mucosa to CRC is thought to take between 5 and 10 years. Therefore 
it may be possible to intervene to interrupt the CRC development by removing 
adenomatous polyps endoscopically.
Clinical features o f colorectal cancer depend on the size and location of the 
tumour. Tumours o f the caecum can remain relatively silent even when quite large 
and may present as iron deficiency anaemia or ill-defined abdominal pain. 
Cancers on the left side of the colon are more likely to present with bowel change 
either increased frequeny, constipation, and change in calibre of the stool or blood 
mixed with the motion. Unfortunately these symptoms are non-specific and 
variable and there is a significant overlap of symptoms with benign conditions 
such as haemorrhoidal bleeding and irritable bowel syndrome. As described 
earlier it is important to achieve an early diagnosis as this greatly increases the 
likelihood of long-term survival.
1.3.5 Treatment o f colorectal carcinoma
In localized disease a cure can be achieved by excision o f the tumour and its 
draining lymph nodes. The outcome in rectal carcinoma can be improved by pre- 
surgical radiotherapy (Ajlouni 2001). In advanced CRC adjuvant chemotherapy 
with 5-flurouracil and folinic acid agents has proven beneficial (Wolmark 1999).
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1.4 The Oesophagus
1.4.1 Normal human oesophagus and gastro-oesophageal junction 
The normal human oesophageal mucosa is made up of the muscularis mucosae 
and the lamina propria that are covered by stratified squamous cells. At the 
gastro-oesophageal junction there is an abrupt transition from the squamous 
epithelium of the oesophagus to the columnar type epithelium of the stomach. The 
mucosa of each region has a specialised function. The oesophageal stratified 
squamous epithelium has primarily a protective role, as the main function of the 
oesophagus is to transfer food from the mouth to the stomach by peristalsis. The 
mucosa o f the stomach is glandular and is capable of secreting gastric juice (acid) 
and protective mucus. Normally the acidic stomach contents are retained in the 
stomach by the action of the lower oesophageal sphincter (LOS). The normal 
function of the lower oesophageal sphincter depends not only on the resting tone 
of the circular smooth muscle o f the muscularis (internal LOS) but also the 
diaphragm (external LOS). The resting tone of the two muscular sheets that make 
up the diaphragm apply a pressure to the outer surface o f the oesophagus. The 
diaphragm separates the thoracic from the abdominal cavity. In the normal 
situation the stomach lies below the diaphragm and at times of increased 
abdominal pressure, due to straining or inspiration, the diaphragm contracts so 
preventing reflux o f the stomach contents in the stomach. As a wave of peristalsis 
delivers a bolus of food to the distal oesophagus there is a reflex co-ordinated 
relaxation of the LOS to allow the bolus to enter the stomach.
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1.4.2 1.4.2 Gastro-oesophageal reflux disease (GORD)
Until relatively recently it was thought that acid reflux into the distal oesophagus 
occurred secondary to a faulty LOS. It has now been shown that in the majority 
of patients suffering from GORD the LOS functions normally most o f the time. 
However, there are periods of LOS relaxation (not associated with a swallow), 
which allow acidic stomach contents to reflux into the distal oesophagus thus 
allowing the mucosal damage characteristic of GORD. These intermittent 
relaxations of the LOS are termed transient lower oesophageal sphincter 
relaxations (TLOSRs, Holloway 1995). During TLOSRs not only the internal 
sphincter o f circular smooth muscle relaxes but also the external sphincter formed 
by the diaphragm, and this is thought to be mediated by a vagal reflex (Neuhuber 
1987).
1.4.3 Barrett’s oesophagus.
The term Barrett’s oesophagus describes the replacement of the normal squamous 
epithelium of the distal oesophagus with columnar cells that demonstrate 
intestinal metaplasia. This change occurs as a consequence of GORD, exposure of 
the squamous epithelium to acidic conditions leading to a metaplastic change in 
the cells. Metaplasia is the process by which cells alter their morphological 
appearance in order to adapt to a change in their local environment. Thus a mature 
fully differentiated cell takes on the character of an entirely different cell type. 
Metaplasia can give rise to an increased risk of neoplasia. In the case of the 
metaplastic change of Barrett’s oesophagus this is very important as it can then
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progress to low grade and then high-grade dysplasia and ultimately 
adenocarcinoma o f the oesophagus. Dysplasia is the histological term to describe 
changes in cell appearance, which occur when the rate of cell division increases 
and there is incomplete maturation of these cells. Dysplastic cells are unstable and 
are capable of becoming neoplastic i.e. developing into a cancer. Adenocarcinoma 
of the oesophagus is rising in prevalence in the Western world. Once cancer has 
developed, the prognosis despite all treatment is extremely poor. Even with best 
treatment five-year survival figures are in the region of 20-30 %. Microscopic 
metastases have often occurred at the time of clinical diagnosis; therefore even 
radical local resection with adjuvant chemotherapy or radiotherapy is unable to 
completely eradicate the cancer.
It would therefore be advantageous to intervene in the neoplastic process before 
cancer has developed. It is thought that adenocarcinoma o f the oesophagus 
develops in areas o f high-grade dysplasia, that in turn develop from low-grade 
dysplasia. The significance of Barrett’s oesophagus is that this metaplastic process 
predisposes to the development of dysplasia and then adenocarcinoma, i.e. 
Barrett’s oesophagus is a pre-cancerous condition. It is therefore desirable to 
intervene in the neoplastic process before cancer develops. Much research has 
been aimed at preventing the progression of normal healthy oesophageal tissue 
into Barrett’s oesophagus in an attempt to interrupt the sequence of changes that 
ultimately lead to the development of oesophageal adenocarcinoma.
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1.5 Background to HO-1 and reactive oxygen species
Heme-Oxygenase (HO) is the rate-limiting enzyme of heme metabolism, 
converting heme to free iron, carbon monoxide (CO) and biliverdin. Tenhunen 
first described its role in heme breakdown in 1968 (Tenhumen 1968).






Heme forms the catalytic subunit of many proteins including the respiratory chain 
cytochromes (p450), cyclo-oxygenase (COX) and inducible nitric oxide synthase 
(NOS2) (Willis 1999; Guo, Shin et al. 2001). There are 3 isoforms of the HO 
enzyme, namely HO-1, HO-2 and HO-3. Each isoform is structurally distinct and 
encoded by different genes. HO-1 has a molecular weight o f 32 kDa and is 
identical to the previously described Heat Shock Protein 32. HO-2 has a 
molecular weight of 36 kDa. HO-2 and HO-3 are constitutively expressed whilst 
HO-1 is the inducible form. HO-2 is expressed at fairly constant levels in cells 
throughout the body. HO-1 is expressed most abundantly in the spleen, the site of 
red blood cell degradation.
HO-1 can be induced by a number of agents or conditions: heme, UVA radiation, 
heavy metals, ischaemia, oxidative stress or cytokines. Cytokines capable of
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HO-1 induction include: IL-1, IL-6, TNFa, and transforming growth factor 
(TGFp). HO-1 has a complex inter-relationship with nitric oxide synthase. For 
example, HO-1 can be activated by nitric oxide, and it can in turn deactivate 
NOS2 by degrading heme (the catalytic subunit o f NOS2) (Tercanu V, Dhouib M 
et al 1998). HO-1 has been identified in many cell types in humans and other 
mammals. It has been suggested that its primary role is unlikely to be heme 
metabolism in all tissues but rather that this inducible form of the enzyme may 
have a more general defensive role by reducing damage caused by sustained 
oxidative stress (Applegate, Luscher et al. 1991).
The fundamental role o f HO-1 is illustrated by a human case-report of HO-1 
deficiency which resulted in growth failure, anaemia, abnormal tissue iron 
deposition, an increased sensitivity to oxidant stress and ultimately premature 
death (Yachie and Koizumi 2001). A mouse model o f HO-1 deficiency showed 
that most animals died in utero and the survivors suffered similar problems to 
those described above in the human case-report (Poss and Tonegawa 1997). HO-1 
can be induced by two groups o f agents: firstly those which produce oxygen free 
radicals (e.g. hydrogen peroxide, UVA and menadione) and secondly by 
substances which reduce the amount of cellular glutathione (e.g. sodium arsenite, 
cadmium chloride and glutathione synthesis inhibitors) (Lautier, et al. 1992).
1.5.1 Heme, structure and function:
Heme acts as a prosthetic group binding tightly to some proteins and thereby 
altering their conformation and facilitating further ligand binding. Heme consists 
of an iron ion held within a cage formed by four pyrrole rings. Haemoglobin is
Expression of HO-1 in the GI tract 38
Introduction
formed by four subunits each containing a heme prosthetic group. The presence of 
these heme prosthetic groups is essential to allow the binding of oxygen. In the 
respiratory chain cytochromes the heme group binds electrons. Heme is 
metabolised by heme-oxygenase to equi-molar amounts o f biliverdin, CO and free 
iron (Fe ) (the reaction intermediates are illustrated in Appendix I). In mammals 
biliverdin is then further metabolised to bilirubin and excreted in bile, the iron 
being recycled in the synthesis of further heme.
Bilirubin is much less soluble in aqueous solution than biliverdin and requires 
conjugation in the liver prior to secretion in bile. It would appear a somewhat 
inefficient metabolic step to convert the readily soluble biliverdin to the relatively 
insoluble bilirubin; however formation of bilirubin may have other beneficial 
properties. Although biliverdin has some anti-oxidant activity this is greatly 
increased when converted to bilirubin. It has therefore been suggested that this 
degradative pathway has evolved to maximise an anti-oxidant influence.
(Stryer 1988)
In a recent population based study from the United States o f America (over 176 
million subjects) a significant association was found between low serum bilirubin 
levels and an increased risk of GI cancer. More specifically a rise in bilirubin of 
1.0 mg/dl was associated with a risk reduction for colorectal cancer equivalent to 
an odds ratio of 0.257 ( 95% Cl 0.254 - 0.260)(Zucker, 2004). The level of 
bilirubin was also shown to be significantly lower in smokers. A cancer protecting 
advantage associated with higher serum levels of bilirubin may account for the 
prevalence of genetic mutations such as Gilbert’s syndrome in which a defective
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form of the enzyme bilirubin glucuronase results in high levels of unconjugated 
bilirubin.
1.5.2 HO-1 has been shown to have a protective influence in other systems 
As already mentioned, HO-1 metabolises heme (which is toxic) to produce 
biliverdin (which acts as an anti-oxidant), carbon monoxide (CO) and free iron. 
There are several lines of evidence to suggest that HO-1 mediates protective 
effects on physiological responses. Firstly, HO-1 has already been shown to be 
active in other systems. Much of the work has been conducted in the pulmonary 
and cardiovascular systems. Of all the products o f HO-1, CO is probably the most 
potent anti-oxidant.
1.5.2.1______ Pulmonary HO-1
In a rat model of acute pleurisy the activity o f HO-1 rose (especially in 
mononuclear cells) as the inflammation progressed and this appeared to correlate 
with the onset o f a resolution o f the inflammatory response (Willis, Moore et al.
1996). In this model the addition of an HO-1 inhibitor resulted in increased 
inflammation and conversely the addition of an HO-1 inducer reduced overall 
inflammation. Exposure to very high concentrations o f oxygen is a commonly 
used model of lung injury. The use of oxygen concentrations greater than 95% 
leads to the development of oxidant injury in a pattern similar to that seen in acute 
respiratory distress syndrome (ARDS). Rats exposed to conditions show 
induction of HO-1 in the pulmonary epithelial cells. (Lee, 1996). In an in vivo 
model rats transfected with an adenovirus capable o f HO-1 production were 
resistant to hyperoxia, and survived longer than untreated controls. Some of this
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protective effect may be mediated by the production of CO. Low levels of CO can 
render rats less vulnerable to hyperoxic injury (Otterbein, 1999). However there 
may be a threshold effect, very high levels of HO-1 and CO may be detrimental 
(Suttner, 1999). The protective effect of CO may be mediated by the down- 
regulation of pro-inflammatory cytokines such as TN Fa and IL lp  and up- 
regulation of IL10 (Otterbein, 2000).
In acute asthma attacks the levels of exhaled CO are increased, suggesting 
increased HO activity induced as a response to acute inflammation (Zayasu,
1997). Smokers have also been shown to have higher levels o f HO-1 expression in 
the pulmonary epithelium (Maestrelli, 2001). There is also a suggestion that 
smokers who develop emphysema are more likely to have an abnormal HO-1 
gene promoter region, perhaps accounting for their susceptibility to develop 
chronic tissue damage in the context of long-term exposure to cigarette smoke 
(Yamada, 2000). A similar defect could affect the chronic inflammation of colitis 
and could perhaps account for the increased risk o f cancer seen in total colitis.
1.5.2.2_______ Cardiovascular HO-1 research
Mouse heart transplant survival (with immuno-suppression) depends on HO-1. 
Rejection occurs if  HO-1 is inhibited or if the recipient mouse is deficient in HO-1 
(Soares, 1998). In the mouse model without the ability to express HO-1 long-term 
survival can be achieved by treatment with low dose CO, again supporting the 
concept that the cytoprotective action of HO-1 is primarily by the action of CO 
(Sato, 2001).
Expression of HO-1 in the GI tract 41
Introduction
1.5.2.3 The inflammatory response of macrophages can be influenced by HO-1 
Macrophages produce an inflammatory response when exposed to bacterial 
lipopolysaccharide (LPS). This response can be modulated by low dose CO in two 
ways. Normally in response to LPS macrophages produce a large amount of the 
pro-inflammatory cytokine TNF a  (Beutler, 1985) and a small amount of the anti­
inflammatory cytokine IL10. However if the macrophages are allowed to over 
express HO-1 or are pre-treated with low dose CO prior to LPS exposure then the 
balance is changed such that the production of TN Fa is greatly reduced and that if 
IL10 greatly increased (Minamino, 2001). This may be directly relevant to the 
pathogenesis and disease activity in IBD, a process that is dependent on an 
aberrant inflammatory response driven in part at least by exposure to bacteria.
1.5.2.4 Animal models show the protective role of HO-1
In a rabbit model o f contact lens related inflammation, increased HO-1 activity 
and HO-1 mRNA were found to correlate with reduced oedema (Laniado- 
Schwartzman, 1997). HO-1 is increased in rat models of cerebral ischaemia and 
less cell damage occurred after ischaemic injury in a transgenic mouse capable of 
overproduction of HO-1 (Panahian, 1999). Similar effects have been 
demonstrated in rat liver models, where stimulation of HO-1 can protect against 
ischaemic injury (Amersi, 1999). Finally, oxidant injury is a potent stimulus for 
apoptosis. It has been shown that fibroblasts over-expressing HO-1 are relatively 
resistant to oxidant stress and resulting apoptosis (Ferris, 1999).
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1.5.3 Reactive oxygen species and chronic inflammation
Over the last two decades there has been increasing interest in the role of reactive 
oxygen species (ROS) in a wide range of chronic inflammatory conditions such as 
rheumatoid arthritis, pancreatitis and atherosclerosis. Cells living in aerobic 
conditions produce these ROS continuously. ROS have the capacity to cause 
tissue damage and a number of defensive mechanisms and enzyme systems have 
evolved to counteract and limit their effects. Various cells, notably neutrophils, 
use controlled production of ROS as part of the inflammatory response. ROS are 
responsible for tissue damage in most inflammatory conditions and control of 
their production and elimination is an attractive therapeutic target.
1.5.3.1_______ROS definition and production
Free radicals are species with one or more unpaired electrons. Unpaired electrons 
are inherently less stable than pairs of orbiting electrons and so free radicals are 
unstable and highly reactive. Free radicals can damage carbohydrates, lipids, 
proteins and DNA. Free radicals are implicated in the production of ROS that are 
present in all cells and it is therefore essential that the production of such free 
radicals be under tight control. The combination o f a radical and a non-radical will 
produce another radical, thus starting a chain reaction of radical production. Such 
a chain can be broken by a radical combining with another radical or by the action 
of anti-oxidant molecule such as vitamin E, vitamin C or anti-oxidant enzymes, 
for example, superoxide dismutase, glutathione peroxidase, glutathione reductase 
or catalase. HO-1 may also act as an important anti-oxidant enzyme in the
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gastrointestinal tract. The broader term, reactive oxygen species, incorporates free 
radicals (with unpaired electrons) and oxidants such as hypochlorite and hydrogen 
peroxide. These oxidants readily participate in reactions to produce free radicals 
such as the hydroxyl radical (OH). Transition metals such as iron play an 
important role in producing free radicals via the Fenton reaction: (Simmonds and 
Rampton 1993)
0 2' + H2O2 -> OH + OH" + 0 2
^  I o  I
In the course o f this reaction ferrous iron (Fe ) is converted to ferric iron (Fe ).
1.5.3.2 The role of iron in the production of the hydroxyl radical.
Transition metals such as iron (Fe ) promote the production o f hydroxyl free 
radicals via the Fenton reaction. As the hydroxyl radical has such damaging 
potential, homeostatic mechanisms have developed to ensure that free transition 
metals are mopped up to prevent uncontrolled ROS production. Studies of iron 
chelation using desferroxamine in pouchitis have yielded encouraging results, (but 
only published in abstract form) (Forbes, A A clinician’s Guide to IBD 2001)
HO metabolises heme to biliverdin, CO and free iron. Biliverdin and its 
metabolite bilirubin are both anti-oxidant (Stocker 1987, Foretsi 2001) and low 
dose CO has anti-inflammatory actions. Iron is potentially pro-oxidant by 
facilitating the Fenton reaction and the production o f the hydroxyl radical;
however the release of iron also stimulates the synthesis o f ferritin (Ferris 1999).
• 2+Free iron (Fe ) binds to the apoprotein to form ferritin. By this mechanism iron is 
sequestered thereby limiting its availability for the Fenton reaction. HO can 
directly stimulate the production of ferritin that itself has anti-oxidant properties.
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1.5.3.3_______ ROS and the pathogenesis of inflammatory bowel disease
The role of ROS in the pathogenesis of IBD has been well described by Rampton 
(Simmonds and Rampton 1993; Millar, Rampton et al. 1996). Accidental 
exposure of the colonic mucosa to hydrogen peroxide (previously used as a 
cleaning fluid) can give rise to an acute inflammatory response very similar in 
appearance to ulcerative colitis (Bilotta and Waye 1989). In the gastrointestinal 
tract free radicals are increased in areas of inflammation (Keshavarzian, Morgan 
et al. 1990). The presence of ROS have been demonstrated using 
chemiluminescence methods in the mucosa of patients with CD and UC, and the 
levels of ROS correlate with disease activity (Simmonds, Allen et al. 1992). (The 
chemiluminescence assay reagents luminol and lucigenin, in the presence of ROS 
have their electrons raised to a higher energy level and when these electrons revert 
to their normal energy levels they release energy in the form of photons, which 
can be quantified using a scintillation counter). ROS are also produced by 
activated polymorphonuclear leukocytes (Repine, Eaton et al. 1979), an increase 
in these cells being a cardinal feature of active inflammatory bowel disease. 
Production of ROS is increased at times of ischaemic reperfusion (Grisham and 
Granger 1988) probably as a result of the induction of xanthine oxidase (which 
produces superoxide). Several theories of the pathogenesis of both types of IBD 
(Crohn’s and UC) invoke a model of ischaemic injury. Crohn’s disease runs a 
more aggressive course in smokers, suggesting that micro vascular injury may 
play a role. This is also supported by the observation that heparin has been shown 
to be of some therapeutic value in the treatment of UC (Gaffney, Doyle et al. 
1995). It has also been suggested that the colonic mucosa may be more vulnerable
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to damage by ROS as the colon is relatively deficient in anti-oxidant defences. 
(McKenzie, Baker et al. 1996). Thus it may be that the tissue damage seen in IBD 
is as a result of the host anti-oxidant defences being overwhelmed by oxidant 
stress.
1.5.3. 4_______IBD drug therapy and anti-oxidants
The action of drugs commonly used to treat IBD may be in part explained by their 
influence on oxidant injury; the 5-aminosalycilate (5-ASA) agents have been 
shown to have a scavenger effect on superoxide radical formation by chelating 
free iron. (Gionchetti, Guamieri et al. 1991). In vitro experiments have confirmed 
that these actions are achieved at 5-ASA concentrations similar to those found in 
the plasma of patients using oral 5-ASA preparations (Christensen, Fallingborg et 
al. 1990). Much higher concentrations of 5-ASAs are required to inhibit cyclo- 
oxygenase and lipoxygenase, suggesting that the therapeutic influence of this 
group of drugs may not involve these enzymes. Glucocorticoids inhibit the 
function of neutrophils and so may reduce ROS production (Baltch, Hammer et al. 
1986). Several studies have investigated the possible therapeutic action of anti­
oxidant agents in IBD. In a study of UC using sulphasalazine maintenance therapy 
the addition of DMSO as an oxygen scavenger or allopurinol (a xanthine oxidase 
inhibitor) resulted in better symptom control and longer periods of remission 
(Salim 1992).
1.5.3.5 Specific features of the action of HO-1 which may be relevant to IBD 
A role for colonic epithelial cells in inflammatory and immune reactions is 
increasingly being recognized (Christ and Blumberg 1997). Ward’s group and
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others have demonstrated that colonic epithelial cells express pro-inflammatory 
enzymes such as COX-2 and NOS2 (Wright, Ward et al. 1997; Weaver, Russo et 
al. 2001) and also secrete members of the chemokine superfamily (IL-8, 
monocyte chemotactic factor-1 (MCP-1), monokine induced by interferon 
y (MIG) and interferon inducible protein 10 (IP-10)) in response to the pro- 
inflammatory cytokines TNFa, IL-1 and IFNy (Kolios, Robertson et al. 1996; 
Kolios, Wright et al. 1999; Dwinell, Lugering et al. 2001). These cytokines in 
turn act as chemo-attractants for cells such as neutrophils, macrophages and T 
cells which are likely to contribute to the inflammatory response within the 
mucosa.
HO-1 offers an anti-inflammatory and anti-oxidant influence in many systems. If 
HO-1 is in some way reduced in activity this may lead to an imbalance of factors 
controlling the inflammatory response and in part account for the uncontrolled 
chronic inflammation that is the cardinal feature o f IBD. A similar hypothesis has 
been put forward to account for the tissue damage o f chronic pulmonary 
inflammation. Patients with emphysema have been found to have polymorphisms 
in the region of the HO-1 gene promoter, suggesting a possible mechanism for 
their susceptibility to increased tissue damage caused by smoking (Yamada, 
Yamaya et al. 2000). Could a similar decrease in HO-1 activity promote IBD? 
Even if HO-1 is found to be expressed in normal levels in IBD tissue it may still 
be possible to produce a beneficial anti-inflammatory effect by stimulating its 
activity within the gut to supra-normal levels.
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At present, there is very little research investigating the role o f HO-1 in the gut. 
However, HO-1 has been shown to be present in rat small intestinal epithelial 
cells (Rosenberg and Kappas 1989), and in the human colonic epithelial cell-lines, 
Caco-2 (Cable, Cable et al. 1993) and DLD-1. In the DLD-1 cell line, pre­
treatment of cells with heavy metals (such as bismuth citrate) or NO donors, 
stimulated HO-1 and inhibited cytokine induced NOS2 activity (Cavicchi, Gibbs, 
Whittle. 2000). It is important to note that NOS2 is up-regulated in areas o f active 
inflammation in IBD (Singer, Kawka et al. 1996). The gastro-protective actions of 
bismuth in peptic ulcer disease are well recognised; however the mechanism of 
this effect remains unclear. As bismuth stimulates HO-1 it is tempting to suggest 
that HO-1 may mediate this effect. Bismuth has also been shown to scavenge 
ROS in animal models of GI injury (Bagchi, 1999).
In a rat model o f colitis induced by addition of trinitrobenzene sulphonic acid 
(TNBS colitis), HO-1 levels were increased in the colon after administration of 
the TNBS enema. When the colon was pre-treated with a HO-1 inhibitor tin 
mesoporphyrin the degree of inflammation caused by the TNBS was greatly 
increased, illustrating a protective action of HO-1 (Wang, Guo et al. 2001). It has 
recently been shown that low concentrations of CO, one o f the products of HO-1 
activity, can inhibit the production of lipopolysaccharide (LPS) induced pro- 
inflammatory cytokines/chemokines (TNFa, IL-1 p, M IP-lp). These cytokines 
have been implicated in the inflammatory events leading to IBD (Otterbein, Bach 
et al. 2000). Thus CO (produced by HO-1) at low concentrations may be 
cytoprotective.
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In other studies, vascular endothelial cells transfected with the HO-1 gene showed 
increased HO-1 mRNA. As a result increased HO-1 activity and reduced 
prostaglandin E2 production occurred. PGE2 is a product of COX-2 that is known 
to be up-regulated in IBD. Increased HO-1 activity was associated with a reduced 
COX-2 activity which returned to normal levels when HO-1 became normal 
(Haider, Olszanecki et al. 2002). For COX-2 to be cataiytically active it requires a 
heme group, therefore reduced cellular levels o f heme following metabolism by 
HO-1 lead to reduced COX-2 activity. The regulation of COX-2 has already been 
the target o f drug treatment in gastro-intestinal inflammation and Barrett’s 
oesophagus. (Buttar, Wang et al. 2002).
1.5.3.6_______HO-1 may mediate the effect of IL-10 in IBD
Knockout mice deficient in IL-10 develop a colitis-like condition when reared in a 
non-sterile environment (Kuhn, Lohler et al. 1993). This illustrates the 
importance o f bacteria in the pathogenesis of IBD and also suggests that IL-10 
may offer a protective influence from this type of chronic inflammation in the gut. 
However, early clinical trials of intravenous IL-10 in Crohn’s disease have been 
somewhat disappointing, showing only marginal clinical improvement, but no 
significant side effects (Fedorak, Gangl et al. 2000). Nevertheless, pre-treatment 
with IL-10 can protect mice from the development of experimental colitis 
(Barbara, Xing et al. 2000). Other studies have revealed that CO can also increase 
LPS-induced expression of the anti-inflammatory cytokine IL-10 (Otterbein, Bach 
et al. 2000). In turn, IL-10 can inhibit LPS-induced production of TNF-a, and 
induction of septic shock (Lee and Chau 2002). Inhibition o f HO-1 protein 
synthesis or activity (using zinc protoporphyrin) significantly reversed the
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inhibitory effect of IL-10. This observation suggests that HO-1 may act as a 
significant downstream effector of IL-10 (Lee and Chau 2002). IL-10 induced 
HO-1 via a p38 mitogen-activated protein kinase (MAPK)-dependent pathway. 
IL-10 treatment resulted in rapid phosphorylation of p38 (within 5 minutes), but 
had no effect on the other MAP kinases ERK or JNK. The inhibitory influence of 
IL-10 on LPS-induced inflammation can be blocked by cyclohexamide, 
suggesting that it involves a newly synthesized protein (Wang, Wu et al. 1994) 
which might be heme-oxygenase.
1.5.3.7______ Relationship between NOS2 and HO-1
NOS2 is the inducible isoform of nitric oxide synthase. There are many 
similarities between the NOS2 and HO-1. Both enzymes result in the production 
of gaseous molecules capable of acting as secondary messengers. NOS2 produces 
NO and HO-1 produces CO. One notable difference in the products is that NO 
has a free electron and acts as highly reactive free radical, whereas CO is 
relatively inert. Many actions of NO have been found since its characterisation in 
the late 1980s as endothelium derived relaxing factor. It has a high affinity for 
heme groups and when bound to soluble guanylyl cyclase results in a four 
hundred fold increase in activity in this enzyme. CO also binds to guanylyl 
cyclase but only increases its activity by a factor o f four. Both NOS2 and HO-1 
can be activated by similar factors: cytokines and oxidant stress.
The action of NO within the gut still remains unclear, with both toxic and 
protective effects having been shown. NOS2 is increased in IBD (Boughton- 
Smith, Evans et al. 1993; Rachmilewitz, Stamler et al. 1995). Inhibition of NOS2 
can reduce the severity of experimental colitis (Rachmilewitz 1995). Increased
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expression of NOS2 leads to increase in NO production, superoxide and 
ultimately peroxynitrite, which cause tissue damage. NOS2 knockout mice are 
deficient in mucosal NO and develop colitis, underlining the mixed effects of NO 
in mucosal inflammation. Work in the DLD gut cell line showed that HO-1 
stimulation can lead to an inhibition of cytokine induced NOS2 activity (Cavicchi, 
Gibbs, Whittle 2000). Similarly chemical inhibition o f HO-1 has been shown to 
result in increased production of NO, both in an in vitro model of muscle strips 
(Chakder 1996) and in macrophages (Turcanu 1998). This down regulatory 
activity o f HO-1 on NOS2 may be mediated by CO (a product of HO-1) binding 
to NOS2 via its heme group. CO has been shown to inhibit the action of NOS2. 
(White 1992). NO generally up-regulates HO-1 and increases CO production.
1.5.3.8_______Recent developments in HO-1 in the Gut
Several studies have confirmed that the induction o f HO-1 prior to oxidant 
stress can reduce tissue damage in animal models o f colitis (Berberat 2005, 
Attuwaybi 2004). The role o f CO in gut motility has attracted considerable 
interest, and the beneficial effect of CO can be blocked by the addition of the 
HO-1 inhibitor tin protoporphyrin (Korolkiewicz 2004).
The Pittsburgh group have explored the use of the products o f HO-1 to 
reduce tissue damage following small bowel transplants in a rat model. This major 
surgery leads to significant post-operative ileus and risk o f septicaemic shock. 
Four groups of rats were studied: (a) controls without surgery, (b) un-operated 
controls exposed to CO for 24 hours, (c) rats who received a small bowel 
transplant, and finally (d) a group who received a small bowel transplant and were 
exposed to CO peri-operatively. Inhaled CO (250ppm for 25 hours) one hour pre
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transplant and 24 hours post transplant reduced the production of pro- 
inflammatory cytokines (IL-ip, IL-6, NOS2 and COX-2) and improved post 
operative gut motility. (Nakao, 2003). In a second study of a very similar design 
the Pittsburgh group investigated the role of biliverdin. Biliverdin administered 
within the peritoneum was shown to increase survival and improve contractility of 
the transplanted gut in the post-operative period. Further experiments confirmed 
that the biliverdin group had a decrease in mRNA expression of the inflammatory 
cytokines IL-6 and IL-lp, a reduction in mRNA expression of NOS2, COX-2 and 
ICAM-1 (intercellular adhesion molecule) and a decrease in neutrophil infiltration 
into the muscularis of the jejunum (Nakao 2004). This pair of studies confirms 
that the 2 of the products of HO-1 can result in functionally significant 
improvement in a small bowel transplant model. In this model the benefits of CO 
and biliverdin are mediated at least in part by different mechanisms: CO improves 
blood flow while biliverdin does not and biliverdin reduces the expression of 
ICAM-1 and reduces the number of infiltrating neutrophils while CO dose not. It 
appears that CO and Biliverdin may have additive or even synergistic 
cytoprotective actions in the gut. The application of these observations in human 
subjects is likely to follow.
1.5.4 ROS and carcinogenesis
The development of cancer depends on multiple steps, involving somatic 
mutations and increased rate o f cell growth. It has been suggested that the 
presence of ROS may stimulate some of the changes essential for carcinogenesis. 
For example, ROS can damage DNA leading to base changes and other mutations. 
ROS may also be responsible for activating potential carcinogens. Expression of
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the ras oncogene protein leads to production o f the superoxide anion and in turn 
to the production of oxygen containing free radicals such as hydroxyl, this may 
account for some of the carcinogenic influence o f this oncogene. (Irani, 1997)
1.5.4.1 Link between chronic inflammation and carcinoma development
Chronic inflammation in the GI tract may lead to an accumulation of ROS by a 
number of possible mechanisms: (a) influx of neutrophils (Williams 1990),
(b) increase in xanthine oxidase activity in epithelial cells (Parks, Bulkley et al. 
1983), (c) increase in Fenton reactions (d) metabolism of arachonidate via the 
lipoxygenase pathway, and finally (e) the action o f bacteria producing ROS. A 
number of cancers have been found to have relatively low levels of anti-oxidant 
enzymes such as superoxide dismuatse and glutathione peroxidase ((Sato, Ito et 
al. 1992), hepatoma and (Jaruga, Zastawny et al. 1994), lung cancer)). When the 
anti-oxidant defences of the cell are overwhelmed then damage will result. Thus a 
loss of anti-oxidant influence may result in increased ROS production that leads to 
DNA damage directly and indirectly via lipid peroxidation (Figure 6, adapted 
from Farhardi 2002). Lipid peroxidation results in the destruction of cellular 
membranes, releasing potentially damaging lysosomal enzymes that can then 
cause further damage to the DNA. Protein oxidation may inactivate homeostatic 
enzymes within the cell cytoplasm. Unsaturated fatty acids when combined with 
hydroxyl radicals undergo lipid peroxidation. This may explain the link between 
diets high in unsaturated fats and an increased cancer risk (Bartoli, Palozza et al. 
1993). This has been modelled in rats where an increase in the malignant 
transformation of colorectal adenomas has been demonstrated in animals fed on a 
diet high in unsaturated fats (Nicholson, Neoptolemos et al. 1991).















GORD O e s o p h a g i t i s * A d e n o c a r c i n o m a  
IBD-> Chronic inflammation*-> Colorectal Carcinoma
Figure 6 Suggested role of ROS in the pathogenesis of GI epithelial damage
(Farhardi et al 2002) ca
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1.5.4.2 ROS and Colon Cancer
The link between ROS within a Western diet and increased colorectal carcinoma 
was suggested by Babbs (Babbs, 1990). He suggested that excess free radical 
production in stool could account for the increased incidence of colorectal cancer 
in the Western world. Intra-colonic free radical production is possible because the 
temperature conditions (stool temperatures between 30 -  60°C) favour superoxide 
production by bacteria. This then drives the Fenton reaction to produce the 
hydroxyl free radical. Aerobic bacteria in the periphery of the stool get sufficient 
oxygen from the mucosal surface of the colon to produce superoxide and 
hydrogen peroxide. Bile pigments act as iron chelators thereby facilitating the 
Fenton reaction and efficient hydroxyl production. The hydroxyl radical may then 
directly cause local damage or lead to the oxidation of pro-carcinogens. 
Conditions within the stool are mainly anaerobic and therefore most iron is 
reduced to the ferrous state (Fe2+). This also favours the production of free 
radicals by the Fenton reaction:
H+ + Fe2+ + H20 2 -> OH' + Fe3+ + H20
9 4 * ^ 4-Thus ferrous iron (Fe ) is converted to the ferric state (Fe ) and hydrogen 
peroxide to the hydroxyl radical.
O2" + H2O2 OH' + OH' + O2 (Fenton reaction).
Again the pattern of high levels of colorectal cancer in the affluent areas in the 
world would support the theory promoted by Babbs. Colorectal carcinoma rates 
are associated with diets rich in meat and consequently high levels of luminal 
iron. A high fat diet also contains more potential carcinogens. The Western diet, 
which has a high level of processed foods and fewer fresh vegetables, is low in 
fibre. A low fibre diet leads to an increased concentration of iron and free radicals
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within the stool and decreased speed of gut transit increasing contact time of stool 
and stool generated ROS with the colonic mucosal surface. Inflammatory 
conditions such as chronic UC may increase the ROS production by the action of 
inflammatory cells within the mucosa, this could account for the increased risk of 
colorectal cancer in extensive colitis of long duration.
1.5.4. 3_______Increased risk of colorectal carcinoma associated with IBD
There is a well-documented increased risk of colorectal cancer associated with 
IBD affecting the colon; both for UC and CD this could be related to excessive 
ROS production. This risk increases with duration of disease and is most marked 
in those patients with total colitis. Cancer is not normally found before 8 - 10  
years o f disease duration, and thereafter the risk is thought to increase by 0.5 -1 % 
per year. Cumulative risk over time is in the order of 2% at 10 years, 8 % at 20 
years and 18 % at 30 years for all patients with UC (Eaden 2001). Best practice 
should be to offer screening colonoscopy to all patients with UC 8 - 1 0  years after 
first symptoms to assess the disease extent (Ridell 1990). For patients with total 
colitis surveillance, colonoscopy is suggested at 3 yearly intervals in the second 
decade of the disease, at 2 yearly intervals in the third and annually in the fourth 
and subsequent decades (Lashner 1988).
1.5.4. 4_______Chronic inflammation and increased risk o f adenocarcinoma
Both chronic colitis and Barrett’s oesophagus predispose to the development of 
adenocarcinoma. Both conditions occur in the setting of chronic inflammation in 
glandular epithelium. The ongoing oxidant stress in these conditions could 
account for the link between chronic inflammation and cancer. These conditions 
favour the generation of free radicals capable of damaging DNA and thereby
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generating mutated cancerous cells Figure 1. It is therefore of interest to study the 
expression of anti-oxidant enzymes such as HO in normal and disease states to see 
if a deficiency in HO-1 could be implicated in the development of cancer.
1.5.4.5_______ Reactive Oxygen Species and Barrett’s Oesophagus
Gastro-oesophageal reflux is associated with the development of oesophagitis and 
Barrett’s oesophagus. Acid is probably the main agent causing this injury but bile 
acids and pancreatic enzymes have also been implicated (Goldberg, 1969; 
Demeester, 1976). The exact mechanism of this injury is not known but may be 
related to increased ROS production. Studies employing luminal enhanced 
chemoluminescence have demonstrated increased ROS production associated 
with oesophagitis and Barrett’s oesophagus. The severity o f inflammation 
correlates with the levels of ROS (Wetscher, 1997). The source o f the ROS in the 
oesophagus is thought to be partly the epithelial cells (which contain xanthine 
oxidase) and partly neutrophils in the lamina propria. Azide and catalase only 
partially inhibit ROS production implying that in the oesopahgus ROS production 
is not solely driven by neutrophils (Olyaee, 1995). In contrast in UC, the ROS 
production is reduced by more than 80% by the application of azide and catalase 
implying a predominantly neutrophil based process (Sedghi, 1993).
Interventional animal studies have shown that the superoxide dismutase which 
scavenges superoxide radicals can reduce the severity of reflux oesophagitis 
(Naya, 1997). It has been suggested that ROS play a role in the development of 
oesophageal carcinoma by mediating oxidative damage to DNA. Animal models
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of carcinoma of the oesophagus have shown that rats develop carcinoma of the 
oesophagus after oesophago-duodenal anastomosis and iron supplementation. In 
one study 60% of rats under such a regime developed carcinoma of the 
oesophagus by 35 weeks post surgery (Chen, 2000). Sacrificed rats with 
oesophageal cancer showed evidence of oxidative damage to DNA (increased 8- 
hydroxy-2’-deoxyguanosine). It has therefore been suggested that iron overload 
and reflux may account for increased oesophageal carcinoma. This may account 
for the increase in incidence in oesophageal cancer in the Western world, in an 
increasing affluent population a diet rich in meat and high in calories leads to 
relative iron overload and obesity which promotes acid reflux. Smoking is a risk 
factor for the development of oesophageal carcinoma and some o f this effect may 
be related to increased endogenous production of ROS in the lungs and blood 
vessels in smokers. Smoking may also reduce endogenous anti-oxidant defences 
(Zhang, 1997).
Barrett’s oesophagus is thought to develop by metaplasia of an immature 
oesophageal stem cell leading to the development of glandular cells (intestinal 
metaplasia). Under the ongoing influence of ROS it has been suggested that these 
metaplastic cells undergo a series of mutations resulting in increasing dysplasia 
and ultimately to the development of invasive carcinoma.
COX-2 has been shown to be raised in Barrett’s oesophagus and adenocarcinoma 
of the oesophagus (Shirvani 2000) and high levels of COX-2 appear to predict 
poor outcome (Buskens 2002). In an endothelial cell model, over-expression of 
HO-1 was associated with a reduction in COX-2 activity and PGE2 production. If
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HO-1 activity is reduced in Barrett’s oesophagus this could result in increased 
COX-2 activity and as a consequence an increased risk of the development of 
adenocarcinoma.
This raises the possibility that reduced oesophageal HO-1 activity in the context 
of GORD might predispose to the development o f Barrett’s oesophagus and 
possibly adenocarcinoma of the oesophagus. If this is confirmed it may offer a 
therapeutic target, by stimulating HO-1 or by adding other anti-oxidant enzymes it 
may be possible to reduce the cancer risk.
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1.6 Aims
1.6.1 Hypothesis:Loss of appropriate regulation of HO-1 may cause a reduction 
in HO-1 levels resulting in an increase in reactive oxygen species in the 
gastrointestinal tract leading to the development of uncontrolled inflammation. 
This reduction in HO-1 may play a role in the development of inflammatory 
bowel disease, colorectal cancer and Barrett’s oesophagus.
1.6.2 To investigate the expression of HO-1 in gut mucosa.
The aim of the present study is to investigate the expression of HO-1 in various 
tissue specimens from the GI tract. A comparison o f immuno-histochemical 
staining between healthy tissue and that from patients with IBD, colorectal cancer 
will be made. A similar comparison between normal oesophagus and Barrett’s 
oesophagus will also be undertaken. The level o f HO-1 expression will be scored 
on a 3-point scale to aid comparison of the different tissue groups. The level of 
HO-1 expression will be scored both in the epithelial layer and in the lamina 
propria.
1.6.3 To investigate the effect of pro-inflammatory cytokines on HO-1 expression. 
This work will be conducted in the colonic epithelial cell line HT29. To validate 
the experimental technique the influence o f cytokine stimulation will first be 
examined by measuring COX-2 from HT29 cells, under the influence o f TNFa. 
HO-1 protein production will be confirmed by Western blotting. The skin 
fibroblast cell line FEK and Jurkat cells will be used to generate HO-1 to act as 
positive control samples for subsequent experimental work. Western blotting for 
HO-1 protein production will assess the effects of TNFa on HT29 cells, to 
investigate whether HO-1 production could be cytokine mediated. The effect of 
stimulation of HT29 cells ultra violet light (UVA) will then be explored.
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2 Materials and Methods
2.1 Methods for immuno-chemical staining
2.1.1 Development of immuno-histochemical staining for Heme Oxygenase
To visualize the presence of HO-1 and HO-2 within tissue specimens the 
technique of immunohistochemical staining was used. A primary antibody 
specific to the protein of interest was first applied to the tissue specimen. A 
secondary antibody, with a peroxidase enzyme attached, was then applied to bind 
to the primary antibody. The peroxidase caused a brown colour change by 
reacting with a substrate chromogen solution (Diaminobenzidine, DAB). Thus the 
antibody targeted colour change (brown stain) could be used to identify the 
location of the proteins of interest.
A commercial kit called ChemMate (K5001/produced by DAKO) was used to 
localise HO. Although the ChemMate kit was developed for use in an automated 
system, it can be adapted to process small batches of slides manually. This is a 
labelled streptavidin biotin system (LSAB) (Figure 7). This system relies on the 
strong affinity between streptavidin and biotin. The secondary antibody has biotin 
attached; this binds to streptavidin that is in turn attached to the horseradish 
peroxidase, thus the peroxidase links to the primary and secondary antibody 
complex. Streptavidin has 4 binding sites for biotin. Some or all can be occupied 
simultaneously so that each biotinylated antibody reacts with several peroxidase- 
conjugated streptavidin molecules thereby increasing sensitivity (See figure 7).







Figure 7 The labelled streptavidin biotin visualisation system (LSAB) 
(HRP = Horseradish peroxidase)
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2.1.2 Standard technique for immuno-histochemistry.
Tissue samples were either biopsies taken at the time of colonoscopy (by MF) or 
gastroscopy or colonic resection specimens. Consent for use of the resection 
specimens was gained from each patient. (See appendix II for patient information 
sheets). The resection specimens were used to allow examination of deeper 
structures of the bowel wall. Tissue was preserved in formalin and embedded in 
paraffin wax. Sections were cut to a thickness of 4 pm and mounted on slides. 
The slides were initially baked at 60°C for one hour to ensure adherence during 
subsequent processing. The slides were then treated to remove the paraffin wax: 
the slides were bathed in a solvent solution (citroclear) twice for periods of 4 
minutes and then rinsed twice in industrial methylated spirit (for periods of 30 
seconds). The slides were then thoroughly washed in tap water before the process 
of antigen retrieval.
The experiments by which the optimal conditions for HO-1 and HO-2 immuno- 
staining were established are presented in the first Results chapter (3.1). Antigen 
retrieval was achieved by boiling the slides in a pressure cooker at full pressure 
for 2 minutes in a sodium citrate solution at pH 6.0. The slides were then rapidly 
cooled in cold water and after rinsing in TBS (pH 9.0) each slide was doused with 
a stream of TBS (pH 9.0) for about 10 seconds. During slide processing the slides 
were kept wet at all times. The slides were then blocked in BSA 5% in TBS 
(pH 9.0) for 1 hour to reduce non-specific background staining. After the 
blocking solution had been gently drained, the primary antibody was applied to 
each slide. The primary antibody solution was incubated overnight at 4°C. The 
optimal primary antibody concentration was found to be 1 in 500 for both HO-1
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and HO-2. The HO-1 and HO-2 antibodies were both polyclonal rabbit antibodies 
bought from Santa Cruz. The primary antibody was diluted in DAKO diluent 
agent (S3022). The primary antibody was then washed off with a solution of TBS 
(pH 9.0) for 10 minutes. At this stage the secondary antibody was applied to each 
slide for 25 minutes at room temperature. The biotinylated secondary antibody 
solution was part o f the ChemMate kit. Slides were then washed in TBS before 
applying the peroxidase blocking solution (agent S2023), 3 drops for 10 minutes. 
This solution contains hydrogen peroxide; the complexes formed between excess 
hydrogen peroxide and endogenous peroxidases are inactive. The slides were then 
washed in TBS once more followed by application o f the horseradish peroxidase 
enzyme solution for 30 minutes. The slides were washed again in TBS and then 
the chromogen solution of diaminobenzidine applied for exactly 5 minutes. 
Finally the slides were washed in tap water and counterstained with haematoxylin 
for 90 seconds. The haematoxylin was first filtered to remove any crystals. The 
slides were then washed in water before briefly submerging in a solution of 70% 
industrial methylated spirit (IMS) and 0.1% hydrochloric acid. Finally to remove 
water from the slides they were submerged in a series of 3 containers of IMS then 
in 3 containers of xylene. The slides were then covered with pertex and 
coverslips.
2.1.3 Scoring immuno-staining
Slides were processed in mixed batches o f healthy and diseased tissue, so that any 
minor variations in conditions would affect both healthy and diseased tissue 
equally. A simple negative control was always used, by omitting the primary 
antibody.
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The intensity o f staining was graded in the epithelium and the lamina propria 
separately. Two independent observers scored the slides. An agreement rate of 
78% was achieved between the two observers (Dr M. Feeney and Dr N. Rooney). 
The score by Mark Feeney was used for statistical analysis.
2.1. 4________ Final standardised conditions (Figure 10.11)
• Block for 1 hour at room temp in 5% BSA.
• Primary antibody at 1 in 500 overnight at 4°C.
• Secondary antibody (standard concentration as per ChemMate).
• TBS at pH 9.0 throughout.
2.1.5 Antigen Retrieval
The slides were heat-treated in a pressure cooker at full pressure for 2 minutes. 
The standard slide preparation described above using formalin and paraffin wax 
leads to some loss of immuno-reactivity. It is thought that cross-linking of 
unrelated proteins within the specimen obscures some epitopes. To regain these 
lost epitopes a number of manoeuvres have been developed. Other groups have 
attempted to use proteolytic enzyme treatment, however in some cases this leads 
to the destruction of the epitopes. It has now become standard practice to heat- 
treat tissue prior to immuno-staining (MacIntyre, 2001). Use o f a pressure cooker




Figure 8  Slides to illustrate the 3 levels of staining intensity in 
oesophageal HO immuno-reactivity, (a) score 0= low, (b) score l=medium 
and (c ) score 2=high intensity. Brown stain indicates expression of the 
protein o f interest. Original magnification 128 x. Full conditions described in 





Figure 9_Slides to illustrate the 3 levels of staining intensity in 
colonic HO immuno-reactivity. (a) score 0= low, (b) score 1= medium 
and (c ) score 2= high intensity. Brown stain indicates expression of the 
protein o f interest.Original magnification 128x. Full conditions described 
in Materials and Methods and summarised in Figure 10.
( c) Simple Control (d) Rabbit Ab excess control
Figure 10 Standardized conditions for HO immuno-reactivity (illustrated 
in small bowel biopsies) After antigen retrieval the slides were treated in a 
blocking solution of 5% BSA in TBS (pH 9.0) for 1 hour. The primary 
antibody solution was incubated overnight at 4°C at a concentration of 1:500, 
the biotinylated secondary antibody secondary antibody was applied to each 
slide for 25 minutes at room temperature. Then the peroxidase blocking 
solution was applied, followed by the horseradish peroxidase enzyme 
solution for 30 minutes. After washing a chromogen solution of 
diaminobenzidine applied for exactly 5 minutes. Finally the slides were 
washed in tap water and counterstained with haematoxylin for 90 seconds. 
Small bowel biopsies were stained with primary rabbit polyclonal anti­
human antibodies supplied by Santa Cruz: (a) HO-1 , (b) HO-2 ( c) Control 
(absence o f primary antibody), (d) Control with non-specific rabbit 
immunoglobulin. Brown stain identifies specific protein expression. Original 
magnification 128 x.
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( c) Simple Control (d)Rabbit Ab excess control
Figure 11 Standardized conditions for HO immuno-reactivity (Colonic).
Colonic biopsy samples and deep resection specimens were stained with 
primary rabbit polyclonal anti-human HO-1 antibody (Santa Cruz) at a 
concentration of 1:500. (a) HO-1 , (b) HO-2 ( c) Control (absence of primary 
antibody), (d) Control with non-specific rabbit immunoglobulin Brown stain 
identifies specific protein expression. Original magnification 128 x. Full 
conditions described in Materials and Methods and summarised in Figure 10
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allows a brief intense period of heat treatment. The mechanism of action of 
antigen retrieval remains controversial. Heat is thought to reverse some of the 
cross-linking that has been induced by the formalin while leaving other cross­
links intact so that the proteins are not denatured.
2.1.6 Antigen Excess / Pre-absorption controls
The best type o f control for immuno-histochemical procedures is the antigen 
excess control. The lowest primary antibody concentration to give a consistently 
positive result is first established. Then the primary antibody is incubated with a 
blocking peptide specific to the protein of interest. The blocking peptide is a small 
highly specific part of the protein of interest, i.e. a section that differentiates it 
from other proteins. The blocking peptide is added in excess by a factor o f ten by 
weight. Thus the entire available primary antibody is specifically bound and 
unavailable to bind to the tissue sample. This mixture is then used instead of the 
primary antibody in the protocol. As there is no unbound primary antibody 
available to bind with the protein of interest this should result in no colour change. 
Unfortunately there were no specific blocking peptides available for the Santa 
Cruz antibodies for HO-1 or HO-2. The possibility of using HO blocking 
peptides from other companies was explored; unfortunately none that specifically 
block the Santa Cruz antibody were available.
Table 3




HO-1 184-288 Upstream from 261
HO-2 293-311 1-291
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Table 3 illustrates the reason a pre-absorption control could not be performed for 
the Santa Cruz antibodies employed. The table shows that the antibody from 
Santa Cruz does not correspond to the blocking peptide that was available from 
Stressgen.As a more crude form of antigen excess control the primary antibody 
was incubated with non-specific rabbit immunoglobulin. These non-specific 
immunoglobulin controls are shown in Figures 10 and 11.
2.1.7 HO-1 and HO-2 Homology
In human HO proteins there is only 42% homology of the amino acid sequences. 
The regions with the greatest similarity are between 125-150 in HO-1 and 144- 
169 in HO-2 (Wilks 2002). This conserved region codes for the distal helix and is 
thought to be the fingerprint motif of the HO proteins. The Santa Cruz antibodies 
are raised against regions distant from this shared amino acid sequence (see table 
3) thus allowing the antibodies to differentiate the two proteins. The Santa Cruz 
antibodies used for HO-1 and HO-2 were both polyclonal rabbit antibodies i.e. 
they react with a variety of epitopes on the target antigen. Polyclonal antibodies 
tend to have a range of low and high affinity against several epitopes; this reduces 
the loss o f specific antibody binding during the washing stages o f the immuno- 
staining process.
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2.1.8 Statistical Analysis
Non-parametric statistical tests were used to analyse the significance of the 
differences in intensity of the HO-1 immuno-reactivity. In this study intensity 
scores are ordinal data i.e. the intervals between scores do not represent a precise 
difference in quantity. Ordinal data can be placed in a meaningful rank order; 
however an intensity score of 2 does not represent intensity twice as great as that 
of a case that scored 1. When comparing two sets of data the Mann-Whitney ‘U ’ 
test (MWU) (also called the Wilcoxon rank-sum test) was used. In the present 
work the MWU test was used to compare the intensity scores from the 
oesophageal biopsies, that is normal vs. Barrett’s oesophagus.
The MWU test is used to test whether two independent groups are drawn from the 
same population. The null hypothesis is that the median values are the same. 
When three sets of data were compared the Kruskal-Wallis test (KW test) was 
used. The KW test was therefore used to compare the data sets from the colon 
biopsies; normal vs. IBD vs. colorectal cancer. When multiple sets o f data are 
compared it becomes more likely that one of the results will reach significance at 
the p=0.05; 1 in 20 results will reach this level of significance by chance. 
Multivariate analysis of variance such as the KW test is designed to adjust for 
this. Neither the MWU nor the KW tests require the data to be normally 
distributed, by analysing by rank order they also avoid problems related to the 
undue influence o f outlying values. Non-parametric tests are less powerful than 
the corresponding parametric test i.e. a non-parametric test is less likely to detect 
a real effect.
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The null hypothesis holds that the scores from the two groups are very similar 
such that if  all the data from the two sets were combined into one large set and 
placed in rank order then the data from both sets would be randomly/evenly 
scattered through the combined set. If the null hypothesis is rejected then when 
the combined set is arranged in rank order, data from one sample should 
concentrate to one end of the scale while data from the other set should be at the 
other end of the scale i.e. suggesting that the two data sets are significantly 
different.
To calculate the MWU statistic the individual data sets are first placed in rank 
order within their own data sets. Then the two data sets are ranked concurrently, 
in ascending order across the combined set. The MWU statistic is related to the 
sum of the ranks for each data set and the number o f variables in each set. 
Similarly the KW statistic is based on the sum of the ranks for each sample set 
when all the sample sets have been ranked in one combined set concurrently.
Where two or more scores are the same, the ranks are adjusted for ties. That is to 
say that if the 9th and 1 Oth scores in rank order of the combined set are identical 
then they each are assigned the score 9.5. If in a three group comparison three 
scores are identical e.g. 5th, 6th and 7th ranked scores are all the same then they 
are all ranked 6th, the next variable in this sequence will then o f course be ranked 
8th. If all the data in the two groups under comparison are identical then there will 
be no difference in the rank order.
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In this study the MINITAB software was used to calculate the p value for the 
MWU statistic. In this case a p value of < 0.05 was taken as significant and such 
values suggested that the null hypothesis (that there was no difference between the 
two groups compared) could be rejected at the 95% confidence level. Where the p 
value was > 0.05 then the null hypothesis was accepted. In all the data presented 
the values were adjusted for ties. A two-tailed test was used, as a difference in 
intensity scoring either increased or decreased was important.
2.1.9 Immuno-staining reagents
Chem Mate Kit K5001
The primary antibody was used in 400 pi o f CHEM MATE diluent.
Na Citrate pH 6 to make upto 10 L
29.4g Na Citrate
Titrate HC1 to achieve a pH of 6
TBS ( Tris buffered saline) made unto 4 L
Tris 24.2 g
NaCL 34.0 g
HC1 To pH 9.0
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2.2 Methods for Western blotting
2.2.1 Western Blotting
The Western blotting technique was used to detect the relative amounts of specific 
proteins. First the protein mixture was passed by electrophoresis through an SDS 
gel (sodium dodecyl sulphate), and then transferred onto a nitro-cellulose gel. The 
distance moved by each protein is determined by its molecular weight. The nitro­
cellulose membrane was then treated with a primary antibody specific to the 
protein o f interest. The membrane was then placed in a solution of a secondary 
antibody (tagged with horse-radish peroxidase) that would bind a specific primary 
antibody. Thus when the secondary antibody is visualised it identifies the relative 
amounts o f the protein under investigation.
2.2.2 Assembly of a Miniprotean gel
Varying concentrations of the SDS gel were used to accommodate proteins of 
differing sizes, 7.5% SDS gel for COX and 10% for HO-1 (See Materials). The 
resolving gel was poured between two glass plates and allowed to set, taking 
approximately 20 minutes. To ensure a level border the gel was overlaid with MQ 
(Milli Q) water, and when the resolving layer had set the MQ was removed and 
the stacking layer poured on top. A plastic comb was then immediately placed 
into the liquid stacking gel to form a series of wells within the stacking gel as it 
set. When this had set the comb was removed to reveal the empty sample wells. 
These were then washed before use. On each gel the first well was loaded with 
molecular weight markers. 20 pi of sample were reloaded into each lane. Initially 
the gel was run at 80 V until the blue marker had reached the resolving gel, then 
the voltage was increased to 180 V until the gel had reached the bottom edge of
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the resolving gel. The gel was then carefully dissembled and placed onto the nitro­
cellulose membrane for transfer of the proteins from the gel to the nitrocellulose 
paper.
2.2.3 Membrane Transfer
Placing the gel on a nitro-ceiluiose paper and applying a voltage difference 
between 2 graphite electrodes across them achieved transfer o f the separated 
proteins. Four dampened pieces of filter paper (cut to the same dimensions as the 
membrane (8.5 x 6 cm)) were stacked on the lower electrode, and onto these was 
placed the nitro-cellulose membrane and then the gel. The pile was then 
completed with 4 more pieces of the filter paper. As each layer was added care 
was taken to remove any air bubbles by gently smoothing the surface with a glass 
roller. The upper electrode was then placed on the top of the stack. To transfer the 
proteins a current of 43 mA per blot was used for 1 hour (0.8 mA/cm per gel). 
After this the stack was dissembled and the membrane stained with Ponceau red 
to confirm that protein transfer had taken place with equal loading and also to 
facilitate the identification of the protein markers whose positions were then 
marked on the membrane with a pencil. The membrane orientation was indicated 
by cutting off a small comer from the top right hand comer o f each gel. The 
Ponceau was then washed off. The primary antibody was applied, and then 
washed off before the secondary antibody was applied. The membrane was then 
ready for developing.
2.2.4 Developing Western Blot
The nitro-cellulose membrane was washed before being treated with Enhanced 
Chemiluminecent (ECL) reagent for 1 minute. The membrane was then wrapped
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in transparent cooking film and placed in a lightproof film case. The membrane 
was exposed to X-ray film for a number o f minutes and then developed in an 
RG11 Fuji X-ray film developer. The hard film was over-laid onto the original 
membrane so that the molecular weight markers could be recorded onto the film. 
Then the membrane was washed in TBS and dried in filter paper. It was stored at 
4° C and later re-analysed for another protein to demonstrate equal loading of 
protein. To make meaningful comparisons o f the relative amounts of the protein 
of interest in each lane it is essential to load equal amounts of total protein. The 
Bradford technique described above allows equal masses of total protein to be 
loaded into each lane, 30 pg in these experiments. Western blots were developed 
with primary antibodies directed against a protein whose concentration would be 
constant in cells independent of the experimental conditions. Thus a Western blot 
for such a protein should produce a consistent band at the same molecular weight 
and of equal intensity across all of the experimental samples, thus demonstrating 
equal loading.
2.2.5 Stripping Western Blot
In order to probe blots a second time for a different protein the blots were stripped 
by immersion for 30 minutes in a stripping buffer at 60°C in a sealed sandwich- 
box. Prior to this treatment with stripping buffer the blots were re-hydrated in 
TBS for 30 minutes. Following this the blots were rinsed in 5 lots of TBS each for 
5 minutes. Once this was completed the blots could then be placed in a blocking 
solution and then exposed to primary and then secondary antibodies as described 
above. Blots were stripped and probed again for a second protein to assess equal 
loading. For COX-2, COX-1 was chosen to assess equal loading, as COX-1 is a
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constitutive version o f the enzyme and does not vary under stimulation. ERK was 
probed to assess equal loading in the case o f HO-1.
2.2.6 Western blotting conditions Table 4
Blocking Primary Ab Secondary Ab
COX 2 5% Marvel 
in TBS Tween 
0.05% azide 









2 Hrs room temp
HO-1 5 % Marvel 
TBS





5 % Marvel 




5 % Marvel 
2 Hrs room temp










1 hr room temp
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2.2.7 Materials for Western blotting
SDS-PAGE Buffers / Western Solutions
4X Resolving Gel Buffer





4 X Stacking Gel Buffer 
0.5 M Tris 
0.4% SDS
Reservoir Buffer 
25 mM Tris 









Semi-Dry Transfer Buffer g/1
48 mM Tris 5.81
39 mM Glycine 2.93
SDS 0.375
20% (v/v) Methanol 200 ml
Washing Buffer (Tris buffered Saline. TBS) g/1 (TOx stock) 
10 mM Tris 12.11 pH 7.5
lOOmMNaCl 58.44
TBS Tween (0.1% Tween 20)
TBS x l 500 ml
Tween 20 0.5 ml
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Table 5





dH20 9.84 ml 8.17 ml 6.85 ml
resolving buffer 5.0 ml 5.0 ml (Stack) 3.0 ml
Bis-Acryl(30%) 5.0 ml 6.67 ml 2.0 ml
10% APS 150pl 150 pi 150 pi
TEMED 15pl 15pl 10 pi
Lysis Buffer
This buffer was made fresh, stored on ice 
(to avoid enzyme degradation).





1 mM sodium vanadate
1 mM sodium molybdate





10 pg/ml Soyabean Trypsin inhibitor
dH20
and used within 4 hours o f production
Per 10 ml of Buffer 
0.5 ml of 1M 
0.3 ml of 5M 
1 ml of 10% (v/v)
1 ml of 100% (v/v)
0.1ml o f 0.5 M pH 8.0 
0.1 ml ofO .lM  
0.1 ml o f 0.1M 
0.2 ml o f 0.5M
5 pi o f 80 mg/ml stock in DMSO 
5 pi of 1.4 mg/ml stock in Methanol 
5 pi o f 20 mg/ml 
5 pi o f 20 mg/ml 
5 pi o f 20 mg/ml 
6.7ml
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Blocking Solution
TBS Tween + 5% non-fat milk (w/v) (Marvel)
5 x Sample Buffer For 50 ml
5% SDS 2.5 g
50% Glycerol 25 ml
200mM Tris -HC1 ph 6.8 10 ml of 1M
MQ Water 14 ml
Bromophenol Blue 1 ml approx
(5% 2-ME add on the day of use 50 pi /I m l)
Stripping Buffer 100 ml
200 mM Tris / HC1 pH 6.8 40 ml
10% SDS 20 ml
H20  40 ml
P Mercapto-ethanol 770 pi
Cell Culture Medium for HT29 
McCoys Medium 5A supplemented with
Medium for freezing HT29 
10% (v/v) DMSO 
40% (v/v) FBS
50% (v/v) Complete McCoy’s Medium
Penicillin 10 units/ml 
Streptomycin 10 mg/ml 
Fungizone 0.5 mg/ml
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2.3 Cell culture
2.3.1 HT29 Cell culture
The HT29 cell line was isolated originally from a primary colonic tumour in a 
44-year-old Caucasian female. These cells retain many of the features of colonic 
epithelial cells: epithelial polarity, the presence of the actin-binding protein and 
enterocyte differentiation. There were some limitations to the use of HT29 cells 
for modelling colonic epithelium. Although this cell line does have a cell surface 
receptor for IL-10, it does not have a fully functioning intracellular portion and as 
a result this cell line does not respond to IL-10 signalling. This is of some 
importance, as IL-10 is known to have anti-inflammatory effects in IBD; (NB IL- 
10 knockout mice develop colitis when reared in non-sterile conditions). 
Interestingly, researchers in Professor Ward’s group at Bath have shown that in 
HT29 cells, IL-4 and IL-13 inhibit COX2 and NOS2 production but IL-10 does 
not have the same effect.
The European Collection of Animal Cultures (ECACC) provided the HT29 cell 
line. Cells were cultured in 80 cm2 flasks. Cells were fed on alternate days with 
Modified McCoy’s medium supplemented with penicillin (lOu/ml), streptomycin 
(lOug/ml) fungizone (0.5ug/ml) and 10% foetal bovine serum (FBS), (this 
combination was referred to as complete McCoy’s Medium). HT29 cells were 
incubated in and atmosphere o f 5% CO2 at a temperature o f 37°C. For Western 
blotting experiments HT29 cells were then cultured to 90% confluency prior to 
stimulation in 6 well plates. Cells in the main culture flask were initially washed
^  I I
with PBS (without Ca and Mg ) to remove the medium then a Trypsin-EDTA 
mixture was added and the cells incubated for 5 minutes. When the cells were
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seen to have detached from the flask the action of the trypsin was inhibited by the 
addition of complete McCoy’s medium. The suspension was then centrifuged for 
5 minutes. The pellet was re-suspended in complete medium and the number and 
viability of the cells assessed using a Neubauer haematocytometer. A small 
sample of the cellular suspension was mixed with Trypan Blue and the proportion 
of dead cells (stained blue) could then be calculated. Cells were then seeded into
'y
the 80 cm flask (for further cultures) or into 6 well plates for Western 
experiments. A variety o f dishes were used and it was found that adequate protein 
yields could be achieved using 6 well plates (Nunc). In these plates 3.5x106 HT29 
cells grew, providing approximately 1.5mg of protein (measured by the Bradford 
method). Cells in flasks and 6 well plates usually took between 5 and 7 days to 
reach confluency.
2.3.2 Cell stimulation
Prior to stimulation the cells were starved overnight in serum free medium. On the 
morning of the stimulation the medium was again changed an hour before the 
addition of the active agents (cytokines or other stimuli were added). To arrest the 
reaction the cell plates were first washed twice with PBS and then 500pl of ice- 
cold lysis buffer was added to each sample before the cells were vigorously 
scraped off the culture plate. The cellular solution was then placed into a 1.5 ml 
specimen tube on ice for 5 minutes, rotated at 4°C for 15 minutes and finally 
centrifuged for 15 minutes. At the end of this process the cells had all undergone 
lysis, and the cellular debris had formed a pellet at the bottom of the specimen 
tube. At this point the sample was stored by freezing to -80°C. Prior to Western
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blotting, protein concentration measurements were carried out by the Bradford 
technique.
2.3.3 Freezing / Thawing HT29 cells
HT29 cells were stored in a solution of 10% DMSO, 40% FBS and 50% McCoy’s 
medium in liquid nitrogen. The cells were thawed by placing the vial in a warm 
water-bath for 5 minutes before transferring to a tube containing 10 ml of warmed 
complete McCoy’s medium. To remove the DMSO this mixture was centrifuged 
for 5 minutes, the supernatant discarded and the pellet re-suspended in complete 
McCoy’s medium prior to seeding in an 80 cm flask. To freeze the cells, 
suspensions of cells were placed in cryotubes (Nunc) cooled gradually overnight 
and then transferred for long-term storage into liquid nitrogen tanks.
2.3.4 Protein concentration measurements by the Bradford Technique.
To make meaningful comparisons between different samples it is essential to load 
the same amount o f total protein for each sample. To measure protein levels the 
amount of protein was estimated by comparing to standard dilutions of bovine 
serum albumin (BSA), typically 2, 5, 10, 20, and 40 pg/ml. Five pi volumes of the 
standard protein solutions and of the specimens under investigation were then 
added to 1 ml of Bradford reagent. 1 OOpl volumes of these solutions were then 
loaded into a 96 well plate and then analysed using a Dynatech MR5000 plate- 
reader. Bradford reagent undergoes a characteristic colour change that is 
dependent on the concentration of the protein added. Thus the standard solutions
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define a curve to which the experimental samples can be compared. Once the 
protein concentration of each sample was known it was possible to dilute each 
sample with differing volumes of lysis buffer so that they all ultimately had the 
same final total protein concentration. Sample buffer was then added and the 
samples boiled for 10 minutes. In this work a final concentration of 150 ug/100 pi 
was used so that when loading the Western gel with 20 pi of each sample these 
contained 30 pg o f protein.
2.3.5 HO-1 Positive Control Preparation
FEK4  cells are a skin fibroblast cell line. When stimulated by UVA radiation they 
produce HO-1 with a good yield of protein being achieved after 6 hours. FEK4  
cells were seeded and grown to 90% confluence on a 90 mm tissue culture plate in 
an incubator. The cells were then drained of their media, which was kept for later 
use during the incubation phase. The cells were then washed in PBS (without 
Ca2+/Mg2+) and placed in PBS with Ca2+/Mg2+(0.01% each). The plates were then 
placed under a UVA light (Uvasun 3000) for a between 50 seconds and 20 
minutes to receive a standard dose of 250 kJ/m2 o f energy at 25°C. The energy 
output of the UVA source was assessed on a daily basis and the duration of 
exposure calculated using a computer-generated algorithm. After this the plates
• ♦ 94 - 94 -were washed in PBS without Ca /Mg . The conditioned medium was then put 
back on the plates before incubation for a further 6 hours. The cells were washed 
twice in ice-cold PBS, and then 1.5 ml of PBS was placed on the cells before they 
were scraped and then transferred to a plastic specimen tube. This was then 
centrifuged 1 minute. The supernatant was discarded and the cell pellet flash- 
frozen in an ethanol/dry ice bath before storing at -80°C.
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The pellet of FEK4 cells was re-suspended in 200 pi of standard lysis buffer. The 
samples were placed on ice for 5 minutes and then rotated at 4°C for a further 15 
minutes, and finally centrifuged for 15 minutes. The supernatant, containing the 
cytoplasmic extract, was then transferred to a new tube.
2.4 Consent for the use of historically stored slides etc
Previous work within the department had been covered by a local consent 
agreement (1990). This agreement was specifically extended for this study. A 
further agreement was sought to cover the molecular analysis of tissue samples in 
IBD, this protocol allowed the use o f stored human tissue i.e. paraffin block 
samples. Where resection specimens were used full consent was gained from the 
patients prior to their operation. It was stressed to the patient that taking part in the 
study was entirely optional and if they took part in the study their operation and 
management would not be altered in any way (see appendix II for patient 
information sheets).
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3.1___________ Optimisation of immuno-staining conditions for HO-1 and HO-2
Standardisation of the optimal conditions for the HO antibodies was conducted on 
normal colon and terminal ileal resection specimens. These specimens had been 
harvested from the colonic end of a right hemi-colectomy specimen performed to 
resect a caecal carcinoma. The normal tissue margins were at least 7 cm distant 
from the cancer. The challenge when developing an immuno-staining technique is 
to maximize the specific staining of the protein of interest while minimizing the 
non-specific background staining. The optimum concentration of primary 
antibody is that which gives a clear colour change specifically identifying the 
target protein without background staining. There is an inverse relationship 
between the incubation time and antibody concentration required to achieve 
optimal conditions. The functional affinity of the antibody refers to the time taken 
for the antibody to reach equilibrium with the tissue antigen. Thus antibodies of 
high functional affinity need relatively little time to achieve a steady state with the 
tissue under analysis. The time to reach equilibrium is also temperature 
dependent. The conditions which were altered to find optimal processing 
included: (a) primary antibody concentration, (b) temperature of the primary 
antibody incubation, (c) duration o f the primary antibody incubation, (d) the 
addition o f a blocking stage to reduce non-specific background staining prior to 
the primary antibody and finally, (e) varying the concentration of the blocking 
solution.
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The first set o f conditions used was as per the ChemMate protocol. Primary 
antibody was applied for 30 minutes at room temperature. A range of HO-1 
primary antibody concentrations were employed: 1:25, 1:50, 1:100, 1:200, 1:400, 
1:800, 1:1000, 1:1500. In Figure 12 two of these concentrations are shown. Both 
these slides show crystal artefacts from haematoxylin. Haematoxylin precipitation 
occurs at cold temperatures; subsequently the haematoxylin was always filtered 
before use. Figure 12 (a) shows heavy brown staining of almost all tissues, while 
Figure 12 (b) shows more selective uptake. The best signals were achieved at 
1:1000 and 1:1500. At these concentrations there was granular staining in the 
cytoplasm of epithelial cells suggesting HO-1 presence in normal colonic 
epithelial cells.
The next variation in conditions to be explored was to extend the primary 
antibody incubation period to 16 hours (overnight) at 4°C. A range of primary 
antibody concentrations was used: 1:1000, 1:1500, 1:2000, and 1:3000. Figure 13 
shows results at 1:1000 (A), 1:3000 (B) and a simple negative control (C, absence 
of primary antibody). Under these conditions 1:1000 appears optimal.
To reduce background staining in the negative control specimens a blocking stage 
was added. Before the primary antibody incubation the slides were bathed in 2 % 
BSA in TBS for 30 minutes. Figure 14 demonstrates the effect o f the addition of 
the blocking solution 2% BSA in TBS for 30 minutes with a variety of primary 
antibody concentrations: 1:1000, 1:3000 and negative control (1:5000 performed 
but not shown). Under these conditions the 1:1000 primary antibody gave the 
clearest result and there was some improvement of the negative control.
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Figure 12 Optimizing HO immuno-staining I. First set of HO-1 
immuno-staining conditions : primary antibody for 30 minutes at 
room temperature. Two concentrations of primary antibody are 
shown : (a) = 1 : 25, (b) = 1:1000 (NB full range o f concentrations 
not shown). Original magnification 128x.
Figure 13 Optimizing HO immuno-staining II. Increased 
duration of primary antibody at 4°: HO-1 primary antibody 
overnight (16 hours) at 4°C. Concentration of primary 
antibody (a) = 1:1000,( b) = 1: 3000, ( c) = control. Full range 
o f concentrations not shown. Original magnification 128x.
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Figure 14 Optimizing HO immuno-staining III.
Additional blocking stage : an attempt to tone down control signal by 
adding a blocking stage with 2% BSA in TBS for 30 minutes prior to 
incubation with the primary antibody overnight at 4 ° C. (a) 1 in 1000, 
(b) 1 in 3000, (c) control. Some reduction in the background staining 
achieved by the blocking step, concentration o f 1 in 1000 appeared to 
be optimal. Original magnification 128x.
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In an attempt to further refine the negative control the period o f blocking was 
extended to 1 hour with 5% BSA in TBS at pH 7.6. Figure 15 shows the results 
obtained using a primary antibody stored at 4°C overnight. Increasing the 
concentration of the BSA blocking solution from 5 to 10% (Figure 16), blocking 
for 1 hour and then applying primary antibody overnight at 4°C was then 
attempted as a final refinement. The higher concentration of blocking solution did 
not yield better results. The best conditions found used blocking with 5% BSA 
for 1 hour and TBS raised to pH 9.0 throughout, with a primary antibody 
concentration of either 1 in 500 or 1 in 1000 (Figure 17).
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Figure 15 Optimizing HO immuno-staining IV.
Variation of the additional blocking stage to attempt to tone down control 
signal: 5% BSA in TBS (pH 7.6) for 1 hour then primary overnight at 4 °  C. 
(a) 1 in 500, (b) control. Original magnification 128 x.
Figure 16 Optimizing HO immuno-staining V.
To investigate whether 10% BSA [(a) and (b)] better than 5% BSA [ ( c) 
and (d )]; (a) and ( c) primary antibody concentration is 1 in 500 and (b) 
and (d) are simple negative controls. The better control with less 
background staining is (d) corresponding to the 5% BSA blocking solution. 
Original magnification 128 x.
Figure 17 Optimizing HO immuno-staining VI.
Variation of the additional blocking stage to attempt to tone down 
control signal: 5% BSA in TBS (pH 9.0) for 1 hour then primary 
overnight at 4 °  C. (a) 1:500, (b) control.
Ultimately these were the best conditions.
Original magnification 128 x.
93
3 Results
3.2 Normal colonic and terminal ileal expression of HO proteins 
demonstrated by immuno-histochemistrv
Having optimised the immuno-staining conditions for HO in human GI tissue a 
series of normal GI tissue sections were analysed. Immuno-staining was 
conducted on both full thickness resection specimens and also biopsy samples. 
Immunostaining was first undertaken in normal tissue to establish the distribution 
of HO-1 and HO-2. The remaining figures of this chapter (Figures 18-23) show 
the immuno-reactivity o f HO-1 and HO-2 in normal small bowel and colonic 
specimens. In these figures positive immuno-staining is demonstrated by brown 
staining for either HO-1 or HO-2 depending on the primary antibody used. The 
principal observation was the expression o f both HO-1 and HO-2 in the epithelial 
cells and in some of the cells of the lamina propria.
3.2.1 Expression of HO-1 and HO-2 in the healthy terminal ileum 
Figure 18 shows immuno-staining of healthy terminal ileum. Figure 18 (a) shows 
HO-1 expression (brown stain is positive for HO-1). Figure 18 (b) shows the 
expression of HO-2 and Figure 18 (c) is a simple control with the omission of the 
primary antibody. HO-1 and HO-2 are expressed in normal terminal small bowel 
in the cytoplasm of the epithelial cells. The nuclei of the epithelial cells line the 
basal margin of the cells (away from the lumen), they stain blue and appear not to 
express either HO-1 or HO-2. Within the lamina propria only some of the 
inflammatory cells express the HO proteins.
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Figure 18 HO immuno-reactivity in the normal terminal ileum.
Immuno-staining for HO-1(A), HO-2(B) and control (C) (brown stain 
positive for protein expression). Demonstrating a similar distribution of 
HO-1 and HO-2 in the cytoplasm of epithelial cells and some 
inflammatory cells in the lamina propria. Slide (C) confirms no staining 
in the control conditions process without the primary antibody. Original 
magnification 128 x. Full conditions described in Materials and Methods 
and summarised in Figure 10. 95
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3.2.2 Expression o f HO-1 and HO-2 in the healthy colon.
Figure 19 demonstrates the expression of HO-1 (Figure 19 (a)) and HO-2 (Figure 
19(b)) in the epithelium and lamina propria o f normal colon. Immuno-staining 
demonstrated the expression of both HO-1 and HO-2 in the epithelial cells in a 
similar fashion to that seen in the terminal ileum with HO expression being in the 
cytoplasm but not in the nuclei. Inflammatory cells in the lamina propria also 
expressed both HO-1 and HO-2 in healthy colonic tissue.
3.2.3 Confirmation that macrophages express HO-1
The inflammatory cells expressing both HO-1 and HO-2 in the terminal ileum and 
the colon sections were identified as macrophages. The expression of HO in 
macrophages is demonstrated in slide Figure 20 (a) and (b). In Figure 20 (a) high 
power view shows strong HO-1 expression in the macrophages in normal lamina 
propria especially in the sub-epithelial region. Figure 20(b) shows a macrophage 
with strong HO-1 expression within a larger population of lymphocytes which do 
not express HO-1. The macrophage has a characteristic morphology easily 
recognised by an experienced histopathologist. Further confirmation that this cell 
population represented macrophages was gained by using a macrophage specific 
immuno-stain a-CD68. Figure 21 (a) shows immuno-staining for HO-1 in normal 
colon with expression in the epithelial cells and in inflammatory cells in the sub- 
epithelial cells of the lamina propria. Figure 21 (b) employs a-CD68 stain 
selective for macrophages and confirms that the sub-epithelial cells expressing 
HO-1 are macrophages, slide processed at University College London.
It would appear that the expression of HO-2 in the lamina propria occurs in a 
wider variety o f cell types than that of HO-1.
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Figure 19 HO immuno-reactivity in the normal colon.
Immuno-staining for HO-1(A), HO-2(B) and control (C) (brown stain positive 
for protein expression). Demonstrating a similar distribution of HO-1 and HO- 
2 in the cytoplasm of epithelial cells and some inflammatory cells in the 
lamina propria. Slide (C) confirms no staining under control conditions 
(processed without the primary antibody). Original magnification 128x. Full 
conditions described in Materials and Methods and summarised in Figure 10.
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Figure 20a HO-1 expression by macrophages in the normal colon Brown 
stain positive for HO-1 in normal colon showing HO-1 expression in 
macrophages in the lamina propria. Original magnification 128x. Full 
conditions described in Materials and Methods and summarised in Figure 10.
Macrophage
Lymphocyte
Figure 20b Small Bowel HO-1 immuno-reactivity (brown stain 
positive for HO-1) showing macrophages expressing HO-1,
lymphocytes stain blue i.e. no HO-1 expression. Original 
magnification 320x. Full conditions described in Materials and 98
Methods and summarised in Figure 10.
Macrophage
Figure 21a Normal colonic biopsy immuno-reactivity for HO-1
(brown stain positive for HO-1) showing HO-1 expression in epithelial 
cells cytoplasm and macrophages in the lamina propria. Original 
magnification 128x. Full conditions described in Materials and Methods 
and summarised in Figure 10.
Macrophage
Figure 21b Normal colonic biopsy a-CD68 immuno-reactivity.
This stain is selective for macrophages and demonstrates the sub- 
epithelial distribution of macrophages within the lamina propria, 




3.2.4 HO-1 expression in deeper structures
Figures 22 (a) and 22 (b) are of neurological tissue within the submucosa o f the 
colon. Figure 22 (a) shows an H+E stain o f a submucosal plexus. Immuno- 
staining confirmed the expression of HO-1 in the parasympathetic ganglion. The 
only previous study of HO expression in human GI tract included only superficial 
biopsy specimens, and therefore did not demonstrate expression of HO-1 in such 
deep structures (Barton 2003). The current work is therefore the first 
demonstration of HO-1 in human GI parasympathetic ganglia. Other deep 
sections also showed the expression of HO-1 in the endothelium of blood vessel 
walls (Figure 23 (a)). Figure 23 (b) provides a high power view o f normal colonic 
epithelium showing the granular brown staining indicative of cytoplasmic 
expression of HO-1. The nuclei (stained blue) are seen at the basal aspect of each 
of the epithelial cells.
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Figure 22a Haematoxylin and eosin stain of neuronal tissue within the
submucosa of the colon. Original magnification 128x..
I
Figure 22b Parasympathetic ganglion shows HO-1 expression.
HO-1 immuno-reactivity in normal colon ( brown stain positive for 
HO-1) showing HO-1 expression in a parasympathetic ganglion. 
Original magnification 128x. Full conditions described in Materials jqj 




Figure 23a HO-1 immuno-reactivity in a colonic resection specimen 
showing submucosal structures : parasympathetic ganglion cells and 
endothelial cells lining the blood vessel stain positive for HO-1, showing 
expression of the protein Original magnification 128x. Full conditions 
described in Materials and Methods and summarised in Figure 10.
Figure 23b High power magnification showing HO-1 
expression in the cytoplasm of colonic epithelial cells.
Original magnification 320 x. Full conditions described in 
Materials and Methods and summarised in Figure 10. 102
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3.3 IBP results
To test the hypothesis that differences in HO-1 could contribute to the 
development of IBD a comparison of the expression of HO in inflammatory 
bowel disease with that in normal tissue was undertaken. Twenty-eight sets of 
biopsies from normal colon were compared with 22 biopsies from cases with IBD. 
A summary of donor details is shown in Appendix III. The scoring system is 
described in detail in the methods section. The slides were processed in mixed 
batches from cases with IBD alongside those from healthy colon so that minor 
difference in slide preparation technique would not affect comparison between 
groups. The intensity of immuno-staining for HO-1 and HO-2 was scored for both 
the epithelium and the lamina propria. The complete data set for normal colon and 
IBD are shown in tables 6 (normal colon) and table 7 (IBD). The mean scores are 
shown in table 8. The principal investigator MF scored all slides. A subset of the 
slides was independently scored by NR to validate the inter observer variation; 
there was a 78% agreement between the two observers.
Mean intensity scores for immuno-staining for HO-1, normal compared to IBD 
Intensity of staining scale: Table 8 . Also see appendix IV for median scores.







HO-1 epithelial 1.62 1.78 p = 0.143
HO-1 lamina propria 1.66 1.88 p = 0.03
HO-2 epithelial 1.83 1.86
HO-2 lamina propria 1.83 1.95
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Table 6 Normal colon im munostaining intensity sc o r e s
MF MF NR NR MF MF
Sam ple Control HO-1 Epith HO-1 LP HO-1 Epith HO-1 LP HO-2 Epith HO-2 LP
50 0 2 1 2 2
51 0 1 1 1 1 2 1
52 0 2 2 2 2 2 2
53 0 2 2 2 1 2 2
54 0 1 2 2 2 2 2
55 0 1 1 1 1 1 1
56 0 1 1 0 0 2 2
57 0 1 1 1 0 2 2
58 0 1 1 1 1 1 1
59 0 2 2 2 2 2 2
60 0 2 2 2 2 1 1
61 0 2 2 2 2
62 0 2 2 2 2
63 0 2 2 2 2
64 0 1 1 2 2
65 1 2 2 2 2
66 0 2 2 2 2
67 0 1 2 2 2
68 0 2 2 2 2
69 0 1 2 1 2
70 0 1 1 1 1
71 1 2 2 2 2
72 0 1 2 1 2
73 2 2 2 2 2
74 0 1 1 2 1
75 1 2 1 2 2
76 1 2 2 2 2
77 1 2 2 2 2
Epith = Epithelial cell score  
LP= Lamina propria score
MF scored  by Dr F een ey  























Table 7 IBD im munostaining intensity sc o r e s
MF MF NR NR MF MF
Control HO-1 Epith HO-1 LP HO-1 Epith HO-1 LP HO-2 Epith HO-2 LP
1
Epith = Epithelial cell score  
LP= Lamina propria score
MF scored  by Dr F een ey
NR scored  by Dr R ooney 105
3 Results
The intensity of immuno-staining for HO-1 was markedly increased in the lamina 
propria (LP) of the biopsies from cases o f IBD. The difference in staining 
intensity between normal LP and the LP of IBD is significant with a p value 
< 0.05 (actual MWU test value p=0.03); the KW for LP scores was 0.048. This is 
illustrated by two representative cases shown in Figure 24 and 25; the biopsies 
from the cases of IBD are in the right hand vertical column. Immuno-staining for 
HO-1 shows that HO-1 expression occurs in macrophages. These cells were 
identified initially by their characteristic morphology. The distribution of the HO- 
1 to the macrophages was confirmed by the additional immuno-staining with a- 
CD68 specific for macrophages see Figure 26 (a) and 26 (b). This study did not 
measure the enzymic activity of the HO-1.
The HO-1 immuno-staining in the epithelium was also higher in IBD than in 
healthy colon biopsies. However this difference did not reach statistical 
significance: KW for epithelial scores 0.78 and MWU test p value was 0.143 
therefore the null hypothesis that there is no difference was accepted. HO-2 (the 
constitutive form of the enzyme) was expressed in both normal tissue and that 
from IBD; however these data were not analysed for statistical significance. 
Figure 27 (a) and (b) show the expression of HO-1 in a case o f Crohn’s disease, a 
lymphoid aggregate being clearly seen at the base o f the glands. Interestingly the 
expression of HO-1 seems to be particularly high in the cells forming the centre of 
the aggregate, possibly reflecting the degree of oxidant stress in this region. 
Figure 27 (c) shows a crypt abscess with the HO-1 expression being high both in 
the epithelial layer and in the lamina propria surrounding the crypt abscess.
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Figure 24 HO immuno-reactivity in normal colon (on the right) compared with
UC (on the left). Brown stains positive for protein expression of (a) HO-1,
(b) HO-2 and (C) control. These slides show that HO-1 and HO-2 are expressed in 
the epithelial cells and the inflammatory cells of the lamina propria of both normal 
colon and that o f UC. Increased staining in the LP of IBD compared to normal 
colon reached statistical significance. Original magnification 128x. Full conditions 
described in Materials and Methods and summarised in Figure 10. 107
(B) HO-2
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Figure 25 HO immuno-reactivity in normal colon (on the left) compared with
UC (on the right) a second example. Brown stains positive for protein expression 
of (a) HO-1, (b) HO-2 and (C) control. These slides show that HO-1 and HO-2 are 
expressed in the epithelial cells and the inflammatory cells o f the lamina propria of 
both normal colon and that of UC. Increased staining in the LP o f IBD compared to 
normal colon reached statistical significance. Original magnification 128x. Full 
conditions described in Materials and Methods and summarised in Figure 10.
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Figure 26 Macrophages express HO-1 in UC, (A) immuno-reactivity for 
HO-1 showing staining in the epithelial cell cytoplasm and macrophages in 
the sub-epithelial region. Full conditions described in Materials and Methods 
and summarised in Figure 10. (B) immuno-stain for a  CD68 confirming that 
the cells in this region are macrophages. Original magnification 128 x.
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(A )  H O -1 Lymphoid aggregate
  ;— 1
Figure 27a HO-1 expression in inflammatory cells within a 
lymphoid aggregate in a case of CD (the lymphoid aggregate is 
in the lamina propria just superficial to the muscularis mucosae). 
Original magnification 128x. Full conditions described in Materials 
and Methods and summarised in Figure 10.
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Figure 27b Lymphoid aggregate positive fro HO-1 (enlarged 
from from slide 27a), showing HO-1 expression in the inflammatory 
cells. Original magnification 128x.
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Figure 27c HO expression in the region of a crypt abscess.
HO immuno-reactivity in a biopsy from a case of Crohn’s 
disease. Immuno-staining for HO-1(A), HO-2(B) and control 
(C) (brown stain positive for protein expression). This slide 
demonstrates a crypt abscess. Original magnification 200x. 
Full conditions described in Materials and Methods and
summarised in Figure 10.
3 Results
3.4 Colorectal carcinoma results
Twenty-eight sets of biopsies from normal colon were compared with 16 sets of 
biopsies from cases with colorectal carcinoma. The intensity of immuno-staining 
for HO-1 and HO-2 was scored for both the epithelium and the lamina propria. A 
summary of donor details is shown in Appendix III. The complete data set of all 
the intensity scores are shown in tables 6, normal colon and table 9, CRC. The 
mean scores are shown in table 10.
Table 10 The mean intensity for immuno-staining for HO-1 comparing normal 
colon with colorectal carcinoma. See Appendix IV for median values.




n= 28 n= 16
Control 0.25 0.56
HO-1 epithelial 1.62 1.85 p = 0.04
HO-1 Lamina propria 1.66 1.88 p = 0.103
HO-2 epithelial 1.83 1.93
HO-2 Lamina propria 1.83 1.93
The intensity o f HO-1 staining was greater in the biopsies o f CRC (colorectal 
carcinoma) than in normal colonic tissue: this is illustrated in Figure 28 and 29. 
This difference was demo
















Table 9 Colorectal can cer im m unostaining intensity sc o r e s
MF MF NR NR MF MF
Control HO-1 Epith HO-1 LP HO-1 Epith HO-1 LP HO-2 Epith HO-2 LP
Epith = Epithelial cell score  
LP= Lamina propria score
MF scored  by Dr F een ey
NR scored  by Dr R ooney 113
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nstrated in both the epithelium and in the lamina propria. The difference in 
epithelial staining reached statistical significance as the MWU value was < 0.05 
(MWU = 0.04). The difference in staining of the lamina propria did not reach 
significance MWU p= 0.103. The control score for the colorectal carcinoma is 
higher than that for the normal tissue and it is possible that the higher background 
staining in this group could account in part for the observed differences in the 
HO-1 stained specimens. The KW value for all colonic epithelial scores was 
greater than 0.05 (KW = 0.078).
Figure 28 demonstrates the differences seen. The biopsies of normal tissue in the 
left hand column are from normal colon and those on the right are from a 
colorectal carcinoma. In the case illustrated both sets of biopsies were taken from 
the same patient during a single colonoscopic examination. The biopsies were 
processed on the same slide. They have therefore been subjected to exactly the 
same immuno-staining conditions, so the differences seen are likely to represent 
real effects. This clearly shows that the intensity of immuno-staining for HO-1 is 
markedly increased in the epithelial cells in colorectal cancer when compared to 
those in normal colonic tissue. Figure 29 illustrates another case of colorectal 
cancer. Again the epithelial cells of the colorectal cancer show high intensity of 
HO-1 immuno-staining suggesting high levels of HO-1 expression.
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Normal tissue Colorectal Carcinoma
(A) HO-1 (A) HO-1
(B) HO-2 (B) HO-2
(C) Control (C) Control
Figure 28 HO immuno-reactivity: On left normal tissue, on the right a 
colonic carcinoma (both sets o f biopsies came from the same patient and 
were processed on the same slide). Demonstrating higher expression of HO-1 
and HO-2 in tissue of the carcinoma as seen by the more intense brown stain. 
Original magnification 128x. Full conditions described in Materials and 
Methods and summarised in Figure 10. n  ^
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Figure 29 HO immuno-reactivity a colonic carcinoma,
this set o f biopsies show increased HO-1 and HO-2 in the 
epithelial cells (brown stain). Original magnification 128x. 
Full conditions described in Materials and Methods and
summarised in Figure 10.
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3.5 Protein production by the HT-29 colonic epithelial cell line 
To investigate the expression of HO-1 in epithelial cells in another way, the 
cancer cell line HT-29 was used. HT-29 cells originate from a single colonic 
adenocarcinoma. This cell line is widely used to study the behaviour o f colonic 
epithelial cells in vitro. The Western blotting technique was used to probe for the 
presence of HO-1 protein, to validate the observations of protein expression that 
had been demonstrated by the immuno-staining experiments. This cell line has 
been extensively used to model the action of inflammatory mediators on colonic 
epithelial cells. Pro-inflammatory cytokines such as IFNa have been shown to 
induce the expression of COX-2 while the anti-inflammatory cytokine IL-13 
abrogates this effect (Weaver 2001). In the present study the HT29 system was 
first investigated by a series of experiments to confirm COX-2 production prior to 
exploring the effect of TNFa and IL-13 on the production o f HO-1.
3.5.1 COX-2 protein production in the HT-29 cell line 
The action o f TN Fa was first studied on HT29 cells. Figure 30 (a) shows a 
COX-2 Western blot of a an experiment stimulating HT29 cells with increasing 
concentrations of TNFa. The cells were harvested 6  hours after stimulation with 
TNFa. Figure 30 (a) demonstrates that at 6  hours a COX-2 protein signal is 
induced by TNFa, and that this signal becomes progressively stronger with 
increasing concentrations of TNFa. A strong signal was achieved with 100 ng/ml 
TNFa and in subsequent work in HT29 cells this was the standard concentration 
of TNFa used. The COX-2 signal corresponds to 74 kDa, and this experiment was 
run on a 7.5% SDS-PAGE gel. The time course of the action o f TN Fa on HT29
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Figure 30a COX-2 protein expression by HT29 cells.
This Western blot demonstrates the COX-2 protein expression by HT29 
colonic epithelial cells when stimulated by increasing concentrations of 
TNF a . This experiment shows a concentration gradient of TNFa at 0, 
20, 50, 100, 250, 500 ng/ml. Six-well plates were used to culture the 
HT29 cells to 90% confluency, each well contained 3.5 x 10 6cells with 
a protein yield o f 1.5mg. Following stimulation the cells were incubated 
at 37° C for 6  hours before harvest. This blot shows that in this cell line 
a good protein yield of COX-2 is achieved after stimulation with TNFa 
at a concentration of lOOng/ml. Representative o f three experiments.
t  t  t  t
0.5 1 4 6  hours
Figure 30b Increasing expression of COX-2 by HT-29 cells over time 
after stimulation with TNF a. This Western blot demonstrates the time 
course of COX-2 protein expression in HT29 cells when stimulated by 
TNFa at a concentration of 100 ng/ml. The cells were incubated at 37 0 C 
and harvested at a series of time intervals: 0.5, 1, 4,and 6  hours after 
stimulation with TNF a . The strongest protein expression o f COX-2 was 
achieved at an interval of 6  hours after stimulation with TNF a. 
Representative of two experiments.
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cells is shown in Figure 30 (b). A weak signal is seen after 4 hours and by 6  hours 
the signal is easily seen. In subsequent work COX-2 protein signals were 
observed after harvesting at 6  hours or later. The COX-2 signal is seen as a 
doublet on Western blotting.
3.5.2 HO-1 protein production by the HT-29 cell line
Initially an in house HO-1 antibody was used to probe for the HO-1 protein. Even 
at high concentrations (1:50) this primary antibody did not give reliable results. A 
commercial antibody from Santa Cruz was bought (H-105, sc-10789) and this 
gave much better results. The same antibody had been used for the immuno­
staining work.
Positive controls for HO-1 protein were created in two ways:
(a) Jurkat cells were stimulated with heme.
(b) FEK cells were treated with UVA light to induce the production of HO-1 
in this skin fibroblast cell line.
Figure 31 (upper blot) shows a Western blot for HO-1 protein in five different 
samples used as positive controls for HO-1. A lysate from Jurkat cells, which 
have been stimulated with heme occupies the first lane of the blot. The next four 
lanes have lysates from FEK cells treated with UVA. All o f these samples 
demonstrate a protein band corresponding to a protein of molecular weight 32 
kDa (HO-1). The protein yield from the FEK cells was lower than that from the 
Jurkat cells as indicated by the weaker signal for FEK cells on the Western blot. 
To produce enough protein to give reliable signal 8  dishes o f FEK cells had to be
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Figure 31 Western blot for HO-1 protein expression in positive control 
samples (upper blot). First lane derived by stimulating Jurkatt cells with heme. 
The other four lanes show HO-1 expression from the skin fibroblast cell line 
FEK stimulated by UVA(250 KJ/m2), then incubated at 37 0 C for 6  hours before 
lysis. The lower blot demonstrates equal loading by probing for HO-2 the 
constitutive form of the enzyme. The sample in lane 2 shows a low protein yield 
for HO-2. Representative of 3 experiments.
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Figure 32 Western blot of HO-1 expression in HT29 cells, 
investigating the effect of UVA treatment on HO-1 expression. The
HO-1 signal is slightly stronger in the cells treated with UVA than in 
those not treated with UVA. The HO-1 signal seen in the HT29s is at a 
marginally heavier weight than that o f the controls (FEK cells) This 
may be related to a modification of the protein such as glycosylation. 
Representative of 3 experiments. 120
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pooled. In the subsequent work the positive controls for HO-1 were either the 
Jurkat cell line stimulated with heme or the skin fibroblast cells exposed to UVA. 
Figure 31 (lower blot) shows equal loading o f the samples in Figure 31 by re­
probing with HO-2 as the primary antibody (sc-11361). NB HO-2 has a slightly 
larger molecular weight (36 kDa). HO-2 is a constitutive form of the enzyme and 
is also present in the FEK cells that have been exposed to UVA.
3.5.3 HO-1 expression is increased by UVA exposure
Figure 32 illustrates the effect of UVA stimulation on HT29 cells harvested at 18 
and 24 hours after the exposure to UVA. The first two lanes are those from the 
light stimulated (250 kJ/mm ) cells and the next two lanes are from those without 
UVA treatment. All the samples have produced HO-1. HO-1 production in those 
cells that have been exposed to UVA is marginally greater than those not exposed
i.e. the resting level of HO-1 expression is increased by exposure to UVA.
3.5.4 HO-1 protein present in cells 1 hour post stimulation (Figure 33)
Figure 33 is an HO-1 Western blot showing the presence o f HO-1 protein in HT29 
cells less than six hours after treatment with TNFa, there is a clear HO-1 signal at 
1 hour post stimulation. The HT29 cells were stimulated with TNFa at a 
concentration of 100 ng/ml. HO-1 protein expression is thought to occur after 6 - 8  
hours. This blot suggests that HO-1 is present in the cells prior to the influence of 
TNFa. This result indicating that the colonic cell line HT29 is likely to express 
HO-1 under resting conditions supports the observations made by immuno- 
histochemistry o f colon biopsies. Immuno-staining showed expression of HO-1 
in normal colonic epithelial cells.
Expression of HO-1 in the GI tract 121
i l  -
tty t
TNF C + + +
Harvest 1 4  6  hours
Figure 33 HO-1 expression in HT-29 cells stimulated by TNFa.
This Western blot for HO-1 protein demonstrates the effect of TNFa 
(100 ng/ml) on HT29 cells. The positive control for HO-1 is marked 
as C( heme stimulated Jurkatt cells). HO-1 expression is present at 1, 
4 and 6  hours post stimulation. This suggests that HO-1 is present 
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Figure 34 Western blot of HO-1 protein expression by HT29 cells 
stimulated by a combination of TNFa(100ng/ml), IFNy (300U/ml) and 
IL-13 (50ng/ml). Cytokines were added at time 0 and the cells harvested at 
6 , 12, 18 and 24 hours. Presence of cytokine indicated by +. HO-1 
expression is seen across all samples, independent of these cytokines. The 




3.5.5 HO-1 expression by HT29 cells after cytokine stimulation 
Figure 34 shows the result of mixed cytokine stimulation of HT29 cells (TNFa 
and IL-13). There are two notable features of this blot. Firstly the FlO-1 signal in 
the HT29s is slightly higher than that in the controls, corresponding to a slightly 
larger molecular weight. This may be because the HO-1 protein is in someway 
slightly modified, for example, glycosylated or phosphorylated. Secondly, the 
HO-1 signal is strongly present across all lanes in the blot suggesting that HO-1 
production is independent of cytokines to which the HT29s have been exposed. 
Cytokine exposure in this experiment did not increase HO-1 protein above basal 
levels. The HO-1 signal is present even in the un-stimulated sample harvested at 6  
or 12 hours. All these samples are harvested after 6  hours. The HO-1 protein 
signal persists in cells to at least 24 hours. The presence of HO-1 in the 
un-stimulated cells is consistent with the observed expression of HO-1 in the 
resting colonic epithelium analysed by immuno-staining. Also in Figure 34 is a 
Western blot for HO-2 that demonstrates equal loading of the previous 
experiment: a faint signal of HO-2 can be seen across all lanes.
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3.6 Results for oesophageal HO-1 and HO-2 immuno-staining 
Twenty normal oesophageal sets of biopsies were compared with biopsies from 
18 cases with Barrett’s oesophagus cases. The intensity of staining for HO-1 and 
HO-2 was scored for both the epithelial region and the lamina propria The 
complete data set of all immuno-staining intensity scores are shown in table 1 1  
(normal oesophagus) and table 12 (Barrett’s oesophagus). The mean scores are 
shown in table 13. In some oesophageal biopsies the sample disintegrated and the 
LP region was lost, in these cases no score was assigned. A summary of donor 
details is shown in Appendix III.
Table 13 Mean intensity scores for immuno-staining for HO-1 
Intensity of staining scale: See Appendix IV for median values.
0 = no stain, 1 = medium intensity, 2 = strong intensity (shown in Figure 8 )
Normal oesophagus 
n = 2 0
Barrett’s oesophagus 
n =  18
MWU test
Control 0 0.17
Epithelial HO-1 1.45 1.82 p = 0.044
LP HO-1 1.4 1 . 8 8 p = 0.026
Epithelial HO-2 1.85 1 . 8 8
LP HO-2 1.55 2 . 0
The difference in epithelial staining in the two groups o f oesophageal biopsies 
was striking. The expression of both HO-1 was much greater in the Barrett’s 
oesophagus than in the normal oesophageal tissue (see Figure 35). A second case 
of Barrett’s oesophagus is illustrated in figure 36, and shown alongside a normal
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Table 11 Normal o e so p h ag ea l  immunostaining intensity sc o r e s  
*Som e biopsy sa m p le s  disintegrated and lost the LP region, therefore no sco re  could be  a ss ign ed
MF MF NR NR MF MF
Sam ple Control HO-1 Epith HO-1 LP HO-1 Epith HO-1 LP HO-2 Epith HO-2 LP
101 0 2 2 2 2 2 2
102 0 1 1 2 1 2 2
103 0 1 1 1 1 2 1
104 0 1 * 1 * 2
105 0 1 1 2 1 2 1
106 0 1 * 1 * 2
107 0 1 ★ 1 * 2 1
108 0 1 * 2 1 2
109 0 2 2 2 * 2 2
110 0 2 ★ 2
111 0 2 * 2
112 0 2 2 2 2
113 0 1 * 2
114 0 2 1 2 1
115 0 1 ★ 1
116 1 ★ 1
117 0 1 * 1
118 0 2 * 2
119 0 2 * 2
120 0 2 2 2 2
Epith = Epithelial cell score  
LP= Lamina propria score
MF scored by Dr F e e n e y
NR scored  by Dr R oo ney  125
Table 12 Barrett's oesophagus immunostaining intensity scores
MF MF NR NR MF MF
S am ple Control HO-1 Epith HO-1 LP HO-1 Epith HO-1 LP HO-2 Epith HO-2 LP
130 0 2 2 2 2 2 2
131 0 2 2 1 1 2 2
132 0 2 2 2 2 2 2
133 0 2 2 2 2 2 2
134 0 2 2 2 1 2 2
135 1 2 2 2 2 2 2
136 1 2 2 2 2 2 2
137 0 2 2 2 2 2 2
138 0 2 2 2 2 2 2
139 0 2 2 2 2 2 2
140 0 2 2 2 2 2 2
141 0 1 1
143 0 1 1 2 2
144 0 2 2 2 2
145 0 1 1 2 2
146 0 2 2 1 2
147 0 2 2 2 2
149 0 2 2 2 2
Epith = Epithelial cell score  
LP= Lamina propria score
MR scored  by Dr F een ey
NR scored  by Dr R ooney 126
HO-1 Control
Figure 35 HO-1 immuno-reactivity of an oesophageal biopsy, HO-1 and 
simple control (absence of HO-1 primary antibody). Normal squamous 
epithelium (Sq) and neighboring Barrett’s Oesophagus (BO) on the same 
slide. This slide demonstrates increased HO-1 expression in the BO tissue 
compared to normal squamous epithelium. Full conditions described in 
Materials and Methods and summarised in Figure 10.
127
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Figure 36 HO immuno-reactivity comparing nomal oesophageal tissue 
with Barrett’s oesophagus: on the left normal squamous epithelium, 
showing very little expression of HO-1 or HO-2, on the right a case of 
Barrett’s oesophagus showing strong expression of both HO-1 and HO-2 in 
the columnar epithelial cells (Epith) and lamina propria (LP).
Original magnification 128x. Full conditions described in Materials 
and Methods and summarised in Figure 10.
3 Results
squamous biopsy. The average immuno-staining score are shown in table 13 (3 
point scale). The greater expression of HO-1 in Barrett’s oesophagus compared to 
normal squamous tissue occurred in both the epithelial cells and the cells of the 
lamina propria.
Comparisons between the two groups were made using the Mann-Whitney U test 
for unpaired data. Significance levels of p< 0.05 (two-tailed) were taken to be 
statistically significant. The differences found for HO-1 staining between normal 
and Barrett’s oesophagus were significant by these criteria for both the lamina 
propria (MWU p=0.026) and the epithelium (MWU p=0.044) in the oesophagus. 
HO-2 expression was very similar in the epithelial cells o f normal and Barrett’s 
oesophagus. The expression of HO-2 was greater in the lamina propria of 
Barrett’s oesophagus. These data were not analysed for statistical significance.
Figure 35 shows a transition point with normal squamous epithelium and Barrett’s 
oesophagus on the same biopsy. This biopsy elegantly illustrates the differences 
of HO-1 expression seen in the two types o f oesophageal tissue. The expression of 
HO-1 in the Barrett’s oesophagus is very strong (score 2) whereas the expression 
in the normal oesophagus is much weaker (score 1). The simple negative controls 
(absence of primary antibody) are shown with score o f 0. This biopsy illustrates 
the differences very clearly. Self evidently the preparation conditions within this 
biopsy were identical so differences in staining between the two types of 
oesophageal tissue are very likely to be real.
Expression of HO-1 in the GI tract 129
3 Results
3.7 HO-1 expression by intestinal spirochaetes. a novel observation:
In one colonic biopsy specimen spirochaetes were identified by light microscopy 
of the H+E slide. An image of spirochaetes is illustrated in Figure 37 (Shah 2001). 
Immuno-staining using the rabbit polyclonal antibodies showed increased 
expression of HO-1 and HO-2. This has not previously been described. This 
observation was confirmed in one normal colonic biopsy and in one with mild 
IBD. The case of IBD is illustrated in Figure 38. The layer o f spirochaete 
organisms clinging to the epithelial surface is easily seen in Figure 38, there is 
strong immuno-staining for both HO enzymes within the spirochaetes.
3.8 Expression of HO-1 in other gastro-intestinal malignancies
A small number of slide samples from other GI malignancies were also immuno- 
stained for HO. Figure 39 shows the results from a gastric adenocarcinoma and 
Figure 40 the results from a gastric carcinoma that had metastasised to the colon. 
In both cases there is strong expression of HO-1 and HO-2 in the cancerous 
epithelium.
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Figure 37 Intestinal spirochaetosis, image (a) is a standard H+E stain 
demonstarting the a false brush boarder, formed by the spirochaetes 
attached longitudinally to the surface of the epithelial cells. Inset bottom 
left is a high power magnification, (b) A high power magnification o f the 
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Figure 38 Spirochaetes express HO-1, dem onstrated by immuno-staining.
HO immuno-reactivity for (a) HO-1 and (b) HO-2 and ( c) control in a mild case 
of IBD, (brown stain is positive for the HO protein ). Spirochaetes are clearly visible 
on the epithelial surface and stain strongly suggesting HO-1 and HO-2 expression. 
Images on the left 128 x magnification and on the right 320 x original magnification. 
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Figure 39 HO immuno-reactivity of a gastric carcinoma,
demonstrating high expression of HO-1 especially in the epithelial cells. 
Original magnification 128x. Full conditions described in Materials and 
Methods and summarised in Figure 10. . __
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Figure 40 HO immuno-reactivity in a gastric cancer which had 
metastasized to the colon. The gastric carcinoma appears to 
express HO-1 particularly strongly. Original magnification 128x.
Full conditions described in Materials and Methods and summarised 
in Figure 10. 134
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3.9 Results summary
3.9.1 Immuno-staining for HO-1 and HO-2
• HO-1 is expressed in the terminal ileum and co-localises with HO-2.
• HO-1 and HO-2 are expressed in normal colonic mucosa in the resting 
state, both in the epithelial cell layer and in the inflammatory cells of 
the lamina propria.
• Expression of HO-1 occurs in the blood vessel walls and in the 
parasympathetic ganglia in the submucosa of the healthy colon.
• Expression of HO-1 increases in conditions of inflammation /cancer. 







Barrett’s Oesophagus Increased Increased
• Immuno-staining in the epithelium of IBD and CRC and the lamina 
propria of CRC were also increased but did not reach statistical 
significance.
• Incidental finding that expression of HO-1 occurs in intestinal 
spirochaetes.
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3.9.2 Summary of protein measurement in HT29 cell line model
• HO-1 expression is marginally increased after UVA treatment. This is 
similar to the known response of the skin fibroblast cell line FEK4 .
• HO-1 protein is expressed in HT29 cells within an hour of stimulation. 
(HO-1 is probably expressed in the un-stimulated state).
• The application of the cytokines TNFa and IL-13 had no great effect 
on the expression of HO-1 by HT29 cells. Basal expression of HO-1 
was seen and not greatly changed by the action of these cytokines.
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4 Discussion
This study demonstrates increased expression of HO-1 in IBD, colorectal 
carcinoma and Barrett’s oesophagus when compared to normal healthy gut tissue. 
HO-1 and HO-2 are expressed in similar distributions. The increased expression 
of HO-1 may represent an appropriate host response to oxidant stress, whereby 
the expression of the inducible form of an anti-oxidant enzyme (HO-1) is 
increased to minimize tissue damage resulting from the presence of reactive 
oxygen species.
4.1 Normal Tissue Discussion
Immuno-staining confirmed the expression of HO-1 in both the lamina propria 
(predominantly in macrophages) and in the epithelial cell layer. The expression of 
HO-1 in normal colon and terminal ileum with no macroscopic features of 
inflammation is an interesting observation. Other research groups have 
demonstrated that in lung tissue there was little or no expression of HO-1 under 
resting conditions. However, after a period of hypoxia, macrophages migrate to 
the region o f the pulmonary epithelium and are the first cells to express HO-1 
(Carraway, Ghio et al. 2000). After a period of several weeks HO-1 expression is 
then seen in the pulmonary epithelial cells. The pattern in the colon would appear 
to be quite different. HO-1, the inducible form of the enzyme appears to be 
expressed even under resting conditions. This may reflect the nature of the 
inflammatory response in the GI tract. The GI tract is constantly exposed to a 
massive luminal antigen load and so may be thought to be in a constant state of 
controlled inflammation. Even in normal tissue the lamina propria has a
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population of inflammatory cells including lymphocytes and macrophages. These 
inflammatory cells in the lamina propria act as sentinels of the host immune 
system, sampling antigenic material and raising the appropriate response.
In this work the macrophages were found to express HO-1. The identity of 
macrophages was determined by their characteristic morphology and the use of a 
macrophage specific immuno-stain a-CD 6 8 . A more elegant way to confirm this 
conclusion would be to double label the same slide. Images of HO-1 expression 
could then be generated before treatment to fully elute the HO-1 antibody then the 
same slide could be stained using oc-CD6 8  antibody to identify macrophages. Co­
localization could then be demonstrated by the superimposition of the two images.
4.2 IBD Discussion
In the IBD specimens studied there was a significant increase in expression of 
HO-1 in the lamina propria. There was also an increase in expression of HO-1 in 
the epithelial cell layer, although this did not reach statistical significance. The 
increase in HO-1 expression seen in the tissue of IBD colonic biopsies may 
represent a physiological response to increased oxidant stress in tissue undergoing 
inflammation. Macrophages have previously been shown to be a rich source of 
HO-1 in pulmonary tissue (Maestrelli, El Messlemani et al. 2001). Macrophages 
are a feature of inflammation of IBD; therefore it could be argued that it is not 
surprising that HO-1 is linked with inflammatory change. It is however significant 
that there is no evidence of a deficiency of HO-1. Thus there is no support for the 
notion that deficiency of HO-1 is a primary event in promoting inflammation in 
IBD.
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4.3 Colorectal Carcinoma Discussion
In the colorectal cancers studied there was a significant increase in the expression 
of HO-1 in the epithelial cell layer when compared to normal colonic biopsies. 
These changes were also seen in a gastric carcinoma and in a gastric carcinoma, 
which had metastasized to the colon. (Figures 39, 40). Perhaps the increased 
expression of this anti-oxidant enzyme is a response to the greater cell turnover. 
Tumours are likely to generate oxidant stress, as cell growth may outstrip the 
vascular supply. However, it is possible that some of the observed differences in 
HO expression are related to the differences in morphology o f the cells in the two 
types of tissue. HO-1 is expressed mainly in the cytoplasm of the epithelial cells. 
Colorectal carcinoma cells tend to be plump having relatively more cytoplasm 
(relative to the nuclear component o f the cell) than normal cells. Even allowing 
for this, the observed intensities of staining for normal and colorectal carcinoma 
biopsies are strikingly different.
HO-2 (the constitutive form of the enzyme) was expressed in both normal tissue 
and that from colorectal cancers. As the data above suggests levels of HO-2 
appear to be raised in the colorectal biopsies although this data was not analysed 
for statistical significance. The HO-1 and HO-2 antibodies used are designed not 
to cross react (see methods).
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4.4 HO-1 protein expression by HT-29 cells
HO-1 expression was demonstrated by immuno-histochemistry in normal colonic 
epithelial cells. Western blotting confirmed that HO-1 protein was expressed in 
the resting state by the HT29 cell line and this observation is in keeping with the 
immuno-staining work. However, it is possible that the culture conditions endured 
by the cell line may expose the cells to continuous oxidative stress. The in vitro 
preparation may therefore express HO-1 as a response to the culture conditions. It 
must also be remembered that the HT-29 cell line is derived from a primary 
colonic tumour and not from normal colonic epithelial cells. UVA stimulation 
could marginally increase HO-1 protein expression by HT-29 cells however 
stimulation with IFNy and TNFa did not increase HO-1 expression above basal 
levels.
4.5 Barrett’s Oesophagus Discussion
Immuno-staining showed HO-1 expression is increased in both the lamina propria 
and the epithelial cell layer in Barrett’s oesophagus when compared to normal 
oesophageal biopsies. So a lack of HO-1 and the resulting anti-inflammatory/anti- 
oxidant influence is not a causal factor in the inflammatory processes leading to 
the development of Barrett’s oesophagus. Rather it would appear that in the 
presence of Barrett’s oesophagus the expression of HO-1 is increased. This may 
represent an appropriate physiological response to the inflammation with the 
change in HO-1 expression appearing to be a secondary event. The increase in 
expression of HO-1 occurs in both the lamina propria and the epithelium.
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4.5 HO expression by intestinal spirochaetes
Parr first described Spirochaete colonisation of the gut in 1923. The term 
intestinal spirochaetosis was introduced by in 1967 by Lee et al. By using electron 
microscopy they visualised a forest o f organisms adherent to the epithelial 
surface of the rectum. Some organisms imaged tangentially showed spiral 
filaments within their cytoplasm, confirming that they were spirochaetes. 
Conventional light microscopy o f H + E slides can also detect spirochaetosis, 
appearing as a false brush border on the epithelial surface. This hazy blue border 
is made up of many long thin spirochaete organisms attached end on to the 
epithelial surface with no evidence of invasion (Figure 37a, Shah 2001). Silver 
staining demonstrates intestinal spirochaetes extremely clearly (Figure 37b). The 
mucosa appears normal at colonoscopy, intestinal spirochaetosis being usually an 
incidental histological finding.
Intestinal spirochaetosis occurs in the faeces in 1.2 % of healthy individuals and in 
hospital patients undergoing rectal biopsy the rate of spirochaetosis ranges from
1.9 % to 6.9% in the U.K. (Takeuchi 1974, Lee 1971). Prevalence rates vary in 
different countries and it is thought, for example, to affect almost the entire 
population in West Africa. High rates have also been reported in homosexual men 
who have a history of anal intercourse (28 to 36 %, Abrams 1998). At least two 
species of spirochaetes have been implicated; Brachyspira pilosicoli and 
Brachyspira aalborgi (Rodgers 1986, Nielson 1983). They vary in length from 
0.5 to 20 pm. They are difficult to grow in culture.
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The pathological significance of intestinal spirochaetosis remains uncertain. Many 
clinicians believe that intestinal spirochaetosis is not associated with GI disease 
and therefore elect not to treat it. This strategy is supported by the observations 
that intestinal spirochaetosis can be present without symptoms, with no obvious 
associated inflammatory response and with no invasion o f the epithelium. One 
interventional study showed a rate of intestinal spirochaetosis o f 5% in 300 
patients who underwent sigmoidoscopy (Neilson 1983). Treatment with neomycin 
did not affect symptoms. However, there have been a series of case reports that 
speculate that chronic infection may cause symptoms of abdominal pain and 
diarrhoea with or without blood. (Heine 2001). Almost invariably such case- 
reports describe relief of symptoms following anti-microbial therapy with 
metronidazole or neomycin. Generally such case reports include only a handful of 
patients and arguably represent a positive reporting bias. Improvement of 
symptoms after treatment with such broad-spectrum antibiotics may represent an 
effect independent o f spirochaetosis.
In two of the colonic biopsies immuno-stained for the HO proteins there was 
coincidental spirochaetosis. In both cases the spirochaetes stained heavily for both 
HO-1 and HO-2 as demonstrated by the observed heavy brown staining Figure 34. 
High levels of expression of HO-1 may represent an evolutionary mechanism 
developed to protect these bacteria from the hostile conditions o f oxidative stress 
within the gut lumen. Other bacteria have developed similar strategies to cope 
with life in the GI tract. For example, Helicobacter pylori employs a urease
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enzyme to create a local alkaline solution to buffer the acidic conditions present in 
the stomach.
4.6 The role of HO-1 in inflammatory conditions in the GI tract 
HO-1 may offer a cytoprotective role within the GI tract. As described in the 
introduction this enzyme has been retained avidly throughout evolution; the 
structure has 90% homology between the rat and human species. HO-1 occurs in 
similar forms across many organisms and many cell types. The metabolism of 
heme could have been localised to a small region of the organism, with the 
enzyme restricted to that organ. The observation that the HO-1 enzyme has been 
retained and can be widely expressed across many cell types may suggest that it 
has a broader cytoprotective function. If HO-1 functions as an inducible anti­
oxidant enzyme with cytoprotective actions it is not surprising that it should be 
induced in states of inflammation or increased cellular turnover such as IBD, 
colorectal carcinoma and Barrett’s oesophagus.
Since the experimental work in this thesis was conducted a small study looking at 
HO-1 in gastritis and a small number o f cases o f colitis has been published 
(Barton 2003). Although this work only looked at biopsy specimens it broadly 
supports the observation that HO-1 is present in normal GI mucosa and increased 
in areas of inflammation in both colitis and helicobacter pylori related gastritis. 
No other work related to HO-1 expression in colorectal cancer or Barrett’s 
oesophagus has yet been published.
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The anti-oxidant influence of HO-1 can be accounted for by considering the result
9 4 -of the metabolism of heme to form CO, free iron (Fe ) and biliverdin. Heme is 
toxic and its metabolites have anti-oxidant properties. Perhaps the most important 
of the products is CO, which is increasingly being recognised as a major 
secondary messenger that at low concentrations can account for many of the
9 +actions of HO-1. Free iron in the ferrous state (Fe ) not only leads to the 
production of free radicals via the Fenton reaction but it also causes increased 
production o f ferritin, which chelates the ferrous iron and is itself an anti-oxidant. 
Biliverdin and its metabolite bilirubin both act as anti-oxidants and free radical 
scavengers.
4.6.1 Is HO-1 always cytoprotective?
In other systems, notably in the lung, induction of HO-1 has been shown to be 
associated with oxidant injury. HO-1 is generally thought to offer a cytoprotective 
influence. This protective effect of HO-1 is supported by the observations that 
inhibition of HO-1 worsens injury (Wang 2001), treatment with an adenoviral 
vector capable of HO-1 production lessens injury (Haider 2002) and that CO one 
of the products of HO-1 metabolism of heme is cytoprotective at low 
concentrations (Otterbein 2000). However there is some evidence that HO-1 may 
not always have a cytoprotective action: there may be a threshold effect whereby 
very high levels o f the HO-1 enzyme products can lead to tissue damage (Suttner 
1999).It may be that overall HO activity is crucial rather than simply that of HO-1 
alone. W eng’s group has shown that in tissues where both HO-1 and HO-2 co- 
localise such as the brain HO-1 interacts with HO-2 and the HO-1 HO-2 complex 
has a lower enzymatic activity than the expected sum of each enzyme (Weng
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2003). It has been suggested that HO-1 binds to HO-2 in such a way as to obscure 
the binding site for heme. The co-localisation seen in the gut may serve to keep 
overall HO enzyme activity within a range that is cytoprotective. This may be 
important in the GI tract. In the examples considered in this study there is 
evidence for very high levels of HO-1 expression in the lamina propria of IBD, 
the epithelial layer o f colorectal cancer and in both layers in Barrett’s oesophagus, 
an interaction between HO-1 and HO-2 must be considered.
The relative lack of expression in normal oesophagus may imply that HO-1 
production is a feature of columnar epithelial cell function (seen in normal colon, 
IBD, colorectal carcinoma and Barrett’s oesophagus but absent from normal 
oesophageal epithelium which is of a squamous type). This may account for the 
very low levels of HO-1 expression found in the normal squamous epithelium of 
the oesophagus. Another explanation of the lack of HO-1 in the oesophagus may 
be related to antigen exposure. The oesophageal epithelium is relatively 
unchallenged by luminal antigens. There is rapid transit o f the undigested food 
bolus through the oesophagus, perhaps this accounts for the much-reduced HO-1 
response in this region compared to more distal parts o f the GI tract.
4.6.2 Limitations of the interpretation of Immuno-staining 
The immuno-staining technique can determine the distribution o f the enzyme in 
the tissue. This technique can identify which cell types express the enzyme (see 
future work on immuno-fluorescence and co-localisation). The density of staining 
can be used to draw semi-quantitative conclusions regarding HO-1 expression.
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Thus in the present work it could be used to indicate that HO-1 expression is 
increased in IBD, colorectal carcinoma and Barrett’s oesophagus.
There are some inherent problems encountered in interpreting the results of 
immuno-staining because other variables can influence the darkness of the 
staining. These include: concentration o f the primary and secondary antibodies; 
incubation time; temperature; level of endogenous peroxidases in the tissue. This 
study attempted to control for these variables by standardising the processing of 
the slides, and by processing them in mixed batches that included normal and 
diseased tissue.
4.6.3 Inter-observer variation in scoring the immuno-staining results
There was only a moderate degree of agreement between the two independent 
observers (MF and NR) with only 78% of the cases being scored the same. These 
were truly independent assessments carried out without coaching or involving 
practice cases. The agreement in future might be improved by further clarification 
of the grading system.
4.6.4 HO-1 enzyme activity
The influence of HO-1 on oxidant stress will depend not only on the level of 
expression of the enzyme but also the activity of the enzyme. Enzyme activity has 
not been measured in the present study. Although this study indicates increased 
expression of HO-1 in IBD, colorectal carcinoma and Barrett’s oesophagus it is 
possible that the enzyme activity may also be altered in these disease states. If the 
enzyme activity were greatly reduced in these disease states then there could be a
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relative lack of anti-oxidant activity. If HO-1 activity is normal in these diseases 
then the increased expression would amount to an appropriate physiological 
response to the increased oxidant stress produced by the disease, not a causal 
event in the disease processes as suggested in the original hypothesis.
If we make the reasonable assumption that the increased expression reflects 
increased enzyme activity then HO-1 of normal activity is expressed in increased 
quantities as a response to the oxidant stress generated by IBD, colorectal 
carcinoma and Barrett’s oesophagus. Therefore the drive for the inflammation is 
not related to a deficiency of HO-1. Oxidant stress, however, remains an 
important influence in conditions characterised by ongoing inflammation and so 
manipulation of HO-1 may still prove to have therapeutic potential.
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4.7 Future work
The present study has opened up and suggested the possibility of future work that 
could refine and extend our knowledge of the relevance o f HO-1 in IBD, 
colorectal carcinoma and Barrett’s oesophagus. Several of these possibilities are 
outline below.
4.7.1 Developments of immuno-staining: co-localisation experiments 
In the present study consecutive slices from the same block o f bowel tissue were 
used to compare the distribution of different proteins in the sample. The first slice 
was stained for the expression of HO-1 and the next for the expression of HO-2. 
Having cut through the same architectural features an approximate comparison of 
the expression of the two enzymes could then be made. A more elegant way to 
investigate the patterns of expression of HO-1 and HO-2 would be to use the 
standard immuno-fluorescence with FITC (fluorescein isothiocyanate) conjugated 
to the secondary antibody. A photograph of the first primary antibody result 
would be taken under the appropriate lighting. Then after soaking off the slide 
cover and treating with KMn0 4  in H2SO4 to remove the HO-1 antibody complex, 
the fluoresciene staining could be repeated with a different primary antibody to 
detect HO-2. The two different proteins of interest could then be visualised as 
different colours and superimposed on the same image to show their differing 
distributions within the same specimen. This technique could also be used to 
compare the expression of HO-1 and also the distribution of macrophages (using 
the a -C D 6 8  antibody). This technique was used by (Donat 1999) to show that in 
the rat ileum a small subset of ganglion cells displayed both HO-2 and NOS 
immuno-reactivity.
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4.7.2 Further analysis o f IBP immuno-staining
It would be interesting to extend this work to a larger number of cases with IBD. 
With a larger data set it would be possible to verify the result that HO-1 
expression is increased in the lamina propria o f IBD and also to explore the trend 
of increased expression in the epithelial cell layer in IBD. It would be interesting 
to subdivide the cases into different disease groups: Crohn’s and ulcerative colitis. 
The inflammatory changes affect the full thickness of the bowel wall in Crohn’s 
disease but are much more superficial in UC. It would also be desirable to 
investigate whether the degree of inflammation (assessed by histological features) 
within the biopsy correlated with the expression o f HO-1: this would be best 
assessed by analysing a series of full thickness sections gained at colectomy for 
IBD. By extending the results from this study it might be expected to establish 
that increased HO-1 expression is associated with inflammation with HO-1 levels 
being highest in the most inflamed specimens.
The effects of drugs on the expression of HO-1 remain unclear; all future cases 
examined should have a full drug history taken including details of exposure to 
corticosteroids, 5 amino-salicylates and non-steroidal anti-inflammatory agents 
(Lavrovsky 1996). In IBD cases it will also be possible to compare samples from 
the same subject at the time of active macroscopic inflammation and during 
remission, and also from areas of the colon that are inflamed and from areas that 
macroscopically appear normal.
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4.7.3 Culture of primary epithelial cells
Work on primary cell collection and culture has begun, but will need significant 
refinement to achieve a model in which primary cell would survive in culture for 
at least 24 hours. To investigate and test the findings suggested by immuno- 
staining further quantitative analysis of HO-1 should be undertaken comparing 
diseased and normal tissue. It would be important to assess HO-1 protein 
expression in the un-stimulated colon primary cells. It would also be possible to 
measure the production of HO-1 mRNA using real-time PCR.
4.7.4 Extend the study of HO-1 expression by Intestinal Spirochaetes
Future work would also study in greater detail the expression of HO-1 by 
intestinal spirochaetes, to validate the expression of HO-1 seen in two cases in the 
present study. To do this a prospective program of specimen collection would 
have to be undertaken. Because of the new legislation (Human Tissue Bill) 
regarding the use of historically held histopathology slides, in the future it will 
only be possible to use stored specimens for research if the patient has granted 
specific permission for this purpose before biopsy was taken. Although intestinal 
spirochaetosis is relatively common, with a prevalence o f approximately 1%, it 
often goes unreported as it is thought to have little pathological significance. 
Therefore an active program of case finding would have to be undertaken.
4.7.5 Does HO-1 modulate anti-inflammatory mediators in the gut?
Given my hypothesis that HO-1 mediates anti-inflammatory effects in the gut, the 
effect of pharmacological manipulation of HO-1 on basal and cytokine-stimulated
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production of pro-inflammatory mediators such as COX-2 and NOS2 could 
be assessed. HO-1 will be selectively stimulated using heme. The role of HO-1 in 
this system could further be investigated by employing its selective inhibitor zinc 
protoporphyrin. Another way to explore the influence of HO-1 on colonic 
epithelial cells would be to incubate the cells in an environment with low levels of 
CO. CO may have anti-inflammatory influence by up-regulation o f IL-10 and 
down-regulation o f TN Fa and IL-1 (Minamino 2001).(similar effects are seen in 
macrophages exposed to LPS). It is also possible that the pro-inflammatory 
cytokines may stimulate expression of HO-1 as part of a negative feedback loop 
to limit tissue damage caused by local inflammation.
4.7.6 Measuring HO-1 enzyme activity
To investigate the role of HO-1 in the inflammatory response, measuring 
functional enzyme activity is more important than measuring enzyme expression. 
To assess HO-1 enzyme activity a variation on a technique described by Carraway 
could be used (Carraway 2000). The homogenised portion o f gut tissue would be 
placed in phosphate buffer with MgCh then sonicated and centrifuged to liberate 
HO enzymes into the supernatant. Immuno-precipitation with an antibody specific 
to HO-1 could be use to separate this isoform of the enzyme from the constitutive 
forms (HO-2 and HO-3). The immuno-precipitate of HO-1 would then be 
incubated with liver cytosol (acting as a source o f bilirubin-reductase) with a fixed 
amount of heme, NADPH, glucose-6-phosphate and G6P-dehydrogenase. The 
amount of bilirubin produced could then be assessed using a spectrophotometric 
analysis to measure the colour change consequent on the production of bilirubin.
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The amount of bilirubin produced would then give a measure o f HO-1 enzyme 
activity. In view of the suggestion by Weng that co-localisation of HO-1 and 
HO-2 may result in a complex of the two enzymes with a lower enzyme activity 
than the sum of the two enzymes, it would also be important to calculate total HO 
activity.
4.7.7 Levels of CO on flatus as a marker of HO-1 activity 
In the respiratory system an increase in exhaled CO produced by the action of 
HO-1 has been found in acute asthma. It has been suggested that the measurement 
o f exhaled CO might predict relapse and offer a marker of disease progression in 
lung disease (Zayasu 1997). It would be interesting to analyse flatus for CO to see 
if levels vary in inflammatory conditions affecting the colon. This could help 
assess whether a change in bowel symptoms was related to a flare of IBD. 
Changes would however be rather non-specific, since this study has shown that 
HO-1 is increased in a number o f different disease states both inflammatory and 
cancer related.
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Conclusion
The original hypothesis suggested that a deficiency o f the anti-oxidant enzyme 
HO-1 could account for some of the inflammatory features associated with IBD 
colorectal carcinoma and Barrett’s oesophagus. The finding in this study that 
increased levels of HO-1 are present in tissue from such disease states indicates 
that a deficiency o f HO-1 is unlikely to be a causal event in the pathogenesis of 
IBD, colorectal carcinoma and Barrett’s oesophagus. Rather, in these diseases 
there appears to be an appropriate physiological response to increased oxidant 
stress that involves the production of the inducible anti-oxidant enzyme HO-1.
Expression of HO-1 in the GI tract 153
6 Appendices











Patient information sheet for bowel inflammation study 
Introduction
You have been invited to take part in a research study. This information sheet is 
designed to help you to understand what the research is about and what it 
involves. Please take some time to read it and discuss it with your hospital doctor. 
Ask about anything that is not clear or if  you need more information. Take time to 
decide whether you would like to take part or not.
Thank you for reading this.
Purpose of this study
In this department we have a special interest into what controls inflammation 
within the human gut. Failure of control of inflammation causes conditions such 
as inflammatory bowel disease and is known to increase the risk o f cancer. Much 
of the work in this area has been performed on abnormal cells and animal 
specimens. To understand exactly what happens in the human gut it is important 
to check this work in tissue from people rather than animals.
Why have I been chosen?
You have been chosen for this study because you are due to have a portion of your 
gut removed at surgery. We would like to take a small part of the bowel that will 
be removed. The size of the piece of the bowel that will be removed will be 
exactly the same regardless o f whether you take part in the study or not. We will 
extract cells from this piece of gut and over a period of 3 weeks perform 
experiments to study inflammation. In total we plan to study about 60 patients in 
this way.
Do I have to take part?
It is up to you to decide whether to take part. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent 
form. If you decide to take part you will be free to withdraw at any stage and do 
not need to explain your reasons for doing so. This will not affect the standard of 
care that you will receive.
What happens if I decide to take part?
If you take part in this study there will be no difference in anyway in your 
operation or your care. The only sample that we require is part of the gut that 
would have been removed any way at your operation.
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What do I have to do?
This study only requires you to give us permission to keep some of the tissue 
removed at your operation. The tissue will be kept for up to 3 weeks and then all 
the cells will be completely destroyed. You will not need to do anything else and 
being part of the study will not affect your treatment in any way.
What are the possible disadvantages of taking part?
As this study does not change your treatment in any way there are no 
disadvantages o f taking part.
What are the possible benefits of taking part?
There will be no direct benefits to you. The information the doctors discover as a 
result o f this study may help them understand why abnormal inflammation causes 
disease in some people. This may help treat other patients in the future.
Will my taking part in this study be kept confidential?
The study doctors will need to access your medical records to check your 
diagnosis. This information will only be available to the researchers directly 
involved in the study. Your results will be kept strictly confidential and any 
information that leaves the hospital will have your name and address removed so 
that you cannot be identified.
What happens to the results if this study?
When we have enough results we will publish the work in a medical journal for 
other doctors to examine. By this method gradually we gain a greater 
understanding of diseases and how to treat them. None of the participants will be 
identified in any report.
Who is organising and funding the research?
One of the consultant gastroenterologists and his team together with a scientist at 
the University of Bath are organising the research. This research project is being 
sponsored by the Wellcome Trust. None of the doctors or scientists are being 
paid to recruit patients.
Who has reviewed the study?
This study has been reviewed by the Bath local research ethics committee.
Contact for further information?
Dr DA Robertson, Consultant gastroenterologist, Royal United Hospital, Bath 
Dr MA Feeney, Research Fellow, Royal United Hospital, Bath 
Tel 01225 428331 Ext 4547




Normal Oesophagus Barrett’s Oesophagus
n 20 18
Average Age 62yr 69yr
Male (%) 12/20 15/18
Female(%) 8/20 3/18
Colon subjects
Normal Colon CRC IBD
n 28 16 22
Average Age 61yr 76yr 47yr
Male (%) 14/28 11/16 8/22
Female (%) 14/28 5/16 14/22
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Appendix IV, Quartile values of HO-1 immuno-staining
Normal IBD CRC
Epi Median 2 2 2
25“ 1 2 2
75th 2 2 2
LP Median 2 2 2
a s 1" 1 2 2
75'" 2 2 2
Oesophageal HO-1 immuno-staining scores
Normal BO
Epi Median 1 2
25“ 1 2
75th 2 2





Median 0 0 0
25'" 0 0 0
75“ 0 0 1
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